Articoli di riviste sul tema "572.829 3"
Segui questo link per vedere altri tipi di pubblicazioni sul tema: 572.829 3.
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Vedi i top-50 articoli di riviste per l'attività di ricerca sul tema "572.829 3".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Vedi gli articoli di riviste di molte aree scientifiche e compila una bibliografia corretta.
1
VAN WALRAVEN, KLAAS. "JUBILEE IN QUESTION - 50 Jahre Unabhängigkeit in Afrika: Kontinuitäten, Brüche, Perspektiven. Edited by Thomas Bierschenk and Eva Spies. Cologne: Rüdiger Köppe, 2012. Pp. 572. €58, paperback (isbn978-3-89645-829-2)." Journal of African History 55, n. 1 (marzo 2014): 106–7. http://dx.doi.org/10.1017/s0021853713000868.
2
Drucker-Brown, Susan. "Franz Kroger Buli-English Dictionary, Münster and Hamburg: Lit-Verlag, 1992, 572 pp., DM 148.80, ISBN 3 88660 820 4 hardcovers, DM 78.80, 3 88660 821 2 paperback." Africa 64, n. 3 (luglio 1994): 443. http://dx.doi.org/10.2307/1160806.
3
Munson, Paul, Juraj Adamik e Lisa Butterfield. "829 Tumor alpha-fetoprotein inhibits cholesterol and steroid metabolism in monocyte-derived dendritic cells". Journal for ImmunoTherapy of Cancer 8, Suppl 3 (novembre 2020): A880—A881. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0829.
Abstract (sommario):
BackgroundHepatocellular carcinoma (HCC) is a particularly lethal malignancy in part due to the potently immune-suppressive tumor microenvironment. The weak immune response is due in part to the presence of tumor alpha-fetoprotein (tAFP), a fetal glycoprotein that is produced by a majority of HCC tumors.1 Previously, we showed that tAFP potently inhibited the differentiation of monocytes to dendritic cells when compared to cord blood-derived normal AFP (nAFP) and ovalbumin (OVA).2 Additionally, we demonstrated that tAFP inhibits lipid metabolism by limiting the expression of fatty acid metabolic enzymes.3 To identify the mechanism whereby tAFP alters dendritic cell metabolism, we analyzed microarray data by a functional enrichment pathway analysis with g: Profiler.4MethodsMonocytes from healthy donors (n=4) were isolated with CD14 magnetic beads and differentiated for five days in the presence of IL-4 and GM-CSF with OVA, nAFP, or tAFP. After five days, we isolated RNA for microarray analysis using an Affymetrix HG-U133A array. R studio generated principal component analysis. Differentially expressed (DE) genes were identified as a 1 log fold change and had adjusted p values ofResultsPrincipal component analysis of the gene expression data revealed that tAFP clustered separately from OVA and nAFP based on PC1 (p = 0.016) and PC2 (p = 0.009) (figure 1). In total, 688 DE genes were identified with 495 upregulated and 193 downregulated (figure 2). Downregulated DE genes between tAFP versus nAFP yielded significantly down regulated pathways including cholesterol (p = 10e-7.5), steroid (p = 10e-7.5), and lipid biosynthesis (p = 10e-6) (figure 3). Interestingly, upregulated DE genes between tAFP versus nAFP included many pathways specific to stress response to metal ions including zinc (p = 10e-10.5) and copper (p = 10e-10) (figure 4).Abstract 829 Figure 1tAFP induces a distinct gene expression profile in monocyte-derived DC’sAbstract 829 Figure 2Identifying differentially expressed genes in OVA, nAFP, and tAFP treated DC’sAbstract 829 Figure 3tAFP downregulates cholesterol and steroid metabolism in DC’sAbstract 829 Figure 4tAFP upregulates stress response to metal ions in DC’sConclusionsIn addition to validating previous data demonstrating tAFP inhibited lipid biosynthesis generally, this is the first report to our knowledge of tAFP inhibiting gene signatures associated with cholesterol and sterol synthesis specifically. Furthermore, we identified significant upregulation of gene pathways corresponding to the stress response genes to metal ions. Notably, functional assays are underway to confirm these gene pathway data. These findings shed new insight into how tAFP perturbs monocyte and DC metabolism and thereby limits differentiation of monocytes to immature dendritic cells. Future insights into how tAFP limits innate immunity could lead to improved immunotherapies for HCC.Ethics ApprovalSamples were collected with informed consent at the University of Pittsburgh (Pitt IRB #UPCI 04-001 and UPCI 04-111).ReferencesChan SL, Mo FKF, Johnson PJ, Hui EP, Ma BBY, Ho WM, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 2009;27:446–52. https://doi.org/10.1200/JCO.2008.18.8151Pardee AD, Shi J, Butterfield LH. Tumor-derived α-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells. J Immunol 2014;193:5723–32. https://doi.org/10.4049/jimmunol.1400725Santos PM, Menk AV, Shi J, Tsung A, Delgoffe GM, Butterfield LH. Tumor-derived α-fetoprotein suppresses fatty acid metabolism and oxidative phosphorylation in dendritic cells. Cancer Immunol Res 2019;7:1001–12. https://doi.org/10.1158/2326-6066.cir-18-0513Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res 2019;47:W191–8. https://doi.org/10.1093/nar/gkz369
4
Krupa, Michał. "Notki recenzyjne". Z Badań nad Książką i Księgozbiorami Historycznymi 10 (11 dicembre 2019): 397–410. http://dx.doi.org/10.33077/uw.25448730.zbkh.2016.131.
Abstract (sommario):
Pamiętniki i relacje w zbiorach rękopiśmiennych BN (wydanie drugie poprawione i rozszerzone), oprac. Danuta Kamolowa przy współudziale Teresy Sieniateckiej, Warszawa: Biblioteka Narodowa, 2015, 539, [1] s., [26] k. tabl.: il., ISBN 978-83-7009-623-6 – Katarzyna Seroka [397-398]
Anna Kocot, Artyści „czarnej sztuki”. Typografia druków Floriana Unglera i Macieja Wirzbięty, Kraków: Księgarnia Akademicka, 2015, ss. 416, ISBN/ISSN 978-83-76384-60-3 – Anna Kamler [398-403]
Justyna Kiliańczyk-Zięba, Sygnety drukarskie w Rzeczypospolitej XVI wieku: źródła ikonografi czne i treści ideowe, Kraków: Wydawnictwo Towarzystwa Naukowego „SocietasVistulana”, 2015, ss. 342, [1]: il., ISBN 978-83-61033-89-9 – Katarzyna Seroka [403-405]
Catalogue of books from the Library of Sigismund II Augustus, King of Poland, in the collection of the National Library of Russia in Saint Petersburg, ed. by Maria I. Tkachenko, Maria Brynda, National Library of Poland (Warsaw), National Library of Russia (Saint Petersburg),Warsaw: National Library of Poland, 2015, 198 [1] s., [21] s. tabl., ISBN 978-83-7009-621-2 – Karolina Figaszewska [405-406]
Joanna Matyasik, Polonika XVI-XVII w. ze zbiorów Wojewódzkiej i Miejskiej Biblioteki Publicznej w Bydgoszczy. Katalog, Bydgoszcz: Wojewódzka i Miejska Biblioteka Publiczna im. Dr. Witolda Bełzy, 2015, ss. 345, ISBN 978-83-85979-21-0; 978-83-62545-86-5 – Agnieszka Chamera-Nowak [406-409]
Polski wkład w przyrodoznawstwo i technikę: słownik polskich i związanych z Polską odkrywców, wynalazców oraz pionierów nauk matematycznoprzyrodniczych i techniki, t. 1-4, red. nauk. Bolesław Orłowski, Warszawa: Instytut Historii Nauki im. Ludwika i Aleksandra Birkenmajerów Polskiej Akademii Nauk, Instytut Pamięci Narodowej – Komisja Ścigania Zbrodni przeciwko Narodowi Polskiemu, 2015, t. 1 ss. 521, t. 2 ss. 437, t. 3 ss. 511, t. 4 ss. 543, ISBN 978-83-8606-229-4; 978-83-8606-228-7; 978-83-7629-829-0; 978-83-7629-828-3; 978-83-7545-569-4; 978-83-7545-570-0 – Sarah Skumanov [409-410]
5
Kumric, Sandra, Dragica Stojic e Bozidar Cekic. "Investigation of hydrogen absorption kinetics on intermetallic compounds Hf2Ni, Hf2Co and Hf2Fe". Chemical Industry 63, n. 3 (2009): 159–62. http://dx.doi.org/10.2298/hemind0903159k.
Abstract (sommario):
Polycrystalline intermetallics Hf2Ni, Hf2Co and Hf2Fe are investigated as the hydrogen absorbers in the temperature range 348 to 823 K, under the constant hydrogen pressure of 1 bar. The absorption process was carried out in typical volumetric apparatus and H/M mole ratios together with rate constants and activation energies for hydrogen absorption reaction were determined. Achieved hydrogen absorption capacities at 573 K are: 0.60, 0.90 and 1.48 and rate constants at 573 K are: 0.38?10-3, 0.55?10-3 and 4.72?10-3 s-1 for Hf2Ni, Hf2Co and Hf2Fe respectively. Determined activation energies are: for Hf2Ni, 38.44 kJ/mol, for Hf2Co, 19.62 kJ/mol and 2.74 kJ/mol for Hf2Fe. From the obtained experimental results, it was concluded that Hf2Fe has the best hydrogen absorption ability among the examined intermetallics.
6
Kaji, Daisuke, Yasunori Ota, Aya Nishida, Hisashi Yamamoto, Hikari Ota, Kazuya Ishiwata, Masanori Tsuji et al. "Clinicopathological Study Of 12 Cases Of EBV-Associated Post-Transplant Lymphoproliferative Disorder (PTLD) After Allogeneic SCT: A Single Institution Analysis Of 825 Transplants Including 572 Cord Blood Transplants In Toranomon Hospital". Blood 122, n. 21 (15 novembre 2013): 3323. http://dx.doi.org/10.1182/blood.v122.21.3323.3323.
Abstract (sommario):
Abstract Background EBV-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is uncommon but one of serious complications after allogeneic stem cell transplantation (SCT). However, there has been little literature published on clinicopathological feature of it. Method We retrospectively investigated 825 cases of allogeneic SCT (unrelated bone marrow (uBM) 159, related peripheral blood (rPB) 94, cord blood (CB) 572) at Toranomon Hospital between January 2006 to November 2012. EBV-PTLD was defined as histologically confirmed Epstein-Barr virus (EBV) positive lymphoproliferative disorder developed after allogeneic SCT. Results We identified 12 cases of EBV-PTLD in our cohort. Cumulative incidence of EBV-PTLD at 2 years was 1.5%. Median time from allogeneic SCT to the diagnosis of EBV-PTLD was 6.4 (2.5-26) months. Eight patients were male and median age at the diagnosis of EBV-PTLD was 58.5 years (28-66). Underlying diseases were acute myeloid leukemia (n=5), myelodysplastic syndrome (1), acute lymphoblastic leukemia (2), adult T cell leukemia-lymphoma (1), aplastic anemia (2) and chronic myeloid leukemia in blastic phase (1). Conditioning regimens were fludarabine-based (n=10) and TBI/CY (n=2). None had an antithymocyte globulin-containing regimen. Donor sources were uBM (n=1) and CB (11). EBV serology before allogeneic SCT was tested in 11 and all were positive. Patients who received CB showed higher incidence of EBV-PTLD compared to those in non-CB cohort (2.2% vs 0.6%, p < 0.01), although patients characteristics was different between them. One patient developed PTLD after third allogeneic SCT. All but one patients had a history of acute graft-versus-host disease (aGVHD) of grade I (n=2), grade II (6) and grade III (3), respectively. Chronic GVHD was observed in 6 patients. Eight patients were on immunosuppressive therapy (IST) with calcineurin inhibitors and/or steroids when EBV-PTLD was suspected for the first time. Although lymphadenopathy was detected by CT scan in 7 patients, surface lymph nodes were swollen in only 3 patients. Initial manifestations were fever in 8, and diarrhea in 5 patients. EBV-PTLD was diagnosed from lymph nodes (n=3), skin (3), bone marrow (2), stomach/duodenum (1), colon (2), and lung (1), respectively. Histological feature was monomorphic (n=4), polymorphic (2), early lesion (4), and unknown (2), respectively. LMP1 and EBNA2 was positive in 40% (4/10) and 30% (3/10), suggesting latency status of I in 50% (6/12), II in 8.3% (1/12), III in 25% (3/12), and unknown in 16.7% (2/12). EBV DNA of 100 copies/microL or above was detected in peripheral blood in all of the EBV-PTLD cases. The treatment for EBV-PTLD were rituximab alone (n=3), rituximab plus reduction of IST (6), rituximab plus cytotoxic chemotherapy (1), and observation alone(2). Although 8 patients achieved response, 2 patients suffered a relapse of EBV-PTLD. With a median follow up of 27.5 (4.1-47.7) months, 2-year overall survival was 46.9% after diagnosis of EBV-PTLD. Eight patients died and 4 are alive without relapse of EBV-PTLD. Causes of death were EBV-PTLD (n=2), relapse of underlying disease(3), infectious disease(2), and aGVHD(1). Conclusion Twelve cases of EBV-PTLD were identified in 825 transplants. Cumulative incidence of EBV-PTLD at 2 years was 1.5%. The incidence of EBV-PTLD after CB transplant was higher than that after non CB transplant, although we have to take into consideration that patients feature was different between them. Response to rituximab and/or reduction of IST was observed in 8 patients with a 2-year overall survival rate of 46.9%. Patients with prior aGVHD and with longer duration of immunosuppressive therapy may have an increased risk of developing EBV-PTLD. Since the initial manifestations were often equivocal, and survival rate after diagnosis is not high, having EBV-PTLD in mind as one of the possibilities is critical for prompt diagnosis. Disclosures: No relevant conflicts of interest to declare.
7
Ovchinnikova, Olga, Yuliya Polishchuk, Konstantin Sukhyy e Elena Shembel. "Non-Aqueous Ionic Liquids Based on Quaternary Ammonium Salts for Lithium-Sulfur Batteries". ECS Transactions 105, n. 1 (30 novembre 2021): 219–23. http://dx.doi.org/10.1149/10501.0219ecst.
Abstract (sommario):
Results of measuring the conductivity of electrolytes with ionic liquids (IL) based on quaternary ammonium salts, promising for innovative lithium-sulfur batteries are presented. The conductivity of IL in a propylene carbonate-dimethylformamide mixture is 5.2·10-4. Sm/cm depending on the solvent ratio. The presence of lithium salt leads to higher values up to 8.9·10-3 Sm/cm.
8
Huang, Jie, Hongtao Zhang, Yong He, Yanqun Zhu e Zhihua Wang. "Evaporation, Autoignition and Micro-Explosion Characteristics of RP-3 Kerosene Droplets under Sub-Atmospheric Pressure and Elevated Temperature". Energies 15, n. 19 (29 settembre 2022): 7172. http://dx.doi.org/10.3390/en15197172.
Abstract (sommario):
The evaporation, autoignition and micro-explosion characteristics of RP-3 kerosene droplets under sub-atmospheric pressure (0.2–1.0 bar) and elevated temperature (473–1023 K) were experimentally investigated using high-speed camera technology. The results showed that the droplet evaporation rate increased monotonically with increasing temperature and pressure under 573–873 K and 0.2–1.0 bar. The decrease of temperature and pressure was obviously detrimental to the successful autoignition of droplets and increased the ignition delay time. Autoignitions at 0.2 bar were very difficult and required an ambient temperature of at least 973 K, which was about 150 K higher than the minimum ignition temperature at 1.0 bar. Sub-atmospheric pressure environment significantly inhibits the formation of soot particle clusters during the autoignition of droplet. Reducing pressure was also discovered to reduce the likelihood of micro-explosions at 673, 773 and 823 K but increase the bubble growth rate and droplet breakage intensity. Strong micro-explosions with droplet breakage time close to 1 ms were observed at 0.6 bar and 773/823 K, showing the characteristic of bubble inertia control growth.
9
Ibelgaufts, H. "Querverweise haufenweise: „Encyclopaedic Dictionary of Genetics”︁. Von R. C. King und W. D. Stansfield. VCH Verlagsgesellschaft, Weinheim 1990. 809 Seiten, 65 Tabellen, DM 275.-. ISBN 3-527-26726-3". Nachrichten aus Chemie, Technik und Laboratorium 38, n. 11 (novembre 1990): 1411. http://dx.doi.org/10.1002/nadc.19900381124.
10
Jones, T. R., R. Zamboni, M. Belley, E. Champion, L. Charette, A. W. Ford-Hutchinson, J. Y. Gauthier et al. "Pharmacology of the leukotriene antagonist verlukast: The (R)-enantiomer of MK-571". Canadian Journal of Physiology and Pharmacology 69, n. 12 (1 dicembre 1991): 1847–54. http://dx.doi.org/10.1139/y91-273.
Abstract (sommario):
Verlukast (MK-679) (3-(((3-(2-(7-chloro-2-quinolinyl)-(E)-ethenyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)-thio)propionic acid) is a potent and selective inhibitor of [3H]leukotriene D4 binding in guinea-pig (IC50 = 3.1 ± 0.5 nM) and human (IC50 = 8.0 ± 3.0 nM) lung homogenates and dimethyl sulfoxide differentiated U937 cell membrane preparations (IC50 = 10.7 ± 1.6 nM) but is essentially inactive versus [3H]leukotriene C4 binding in guinea-pig lung homogenates (IC50 values of 19 and 33 μM). Functionally, when tested at 60 nM, it antagonized contractions of guinea-pig trachea (GPT) induced by leukotriene C4, leukotriene D4, and leukotriene E4 (respective −log KB values of 8.6, 8.8, and 8.9) and contractions of human trachea (HT) induced by leukotriene D4 (−log KB value 8.3 ± 0.2). In contrast, verlukast (20–200 nM) failed to antagonize contractions of GPT induced by leukotriene C4 in the presence of 45 mM L-serine borate. Intravenous (i.v.) and aerosol verlukast antagonized bronchoconstriction (BC) induced in anaesthetized guinea pigs by i.v. leukotriene D4 but did not block BC to arachidonic acid or histamine. Intraduodenal verlukast (0.25 mg/kg) antagonized leukotriene D4 (0.2 μg/kg) induced BC in guinea pigs. Oral and aerosol administration blocked leukotriene D4-induced BC in conscious squirrel monkeys. Orally administered compound also blocked ovalbumin-induced BC in conscious sensitized rats treated with methysergide (3 μg/kg). The pharmacological profile for verlukast is similar to that of the racemic compound, MK-571. Verlukast is currently in clinical development for the treatment of asthma and related diseases.Key words: verlukast, MK-679, leukotriene D4 antagonist, airway smooth muscle.
11
Kam, Audrey E., Gopichand Pendurti, Umang H. Shah, Mohammad Haroon Ghalib, Imran Chaudhary, Sengottuvel Viswanathan, Ioannis Mantzaris e Sanjay Goel. "Clinical outcome and prognosis of metastatic colorectal cancer (mCRC) patients (pts) on phase 1 trials: A single institution experience from 1999 to 2016." Journal of Clinical Oncology 36, n. 4_suppl (1 febbraio 2018): 828. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.828.
Abstract (sommario):
828 Background: Pts with mCRC who progress on all standard therapies have a poor prognosis and limited therapy options. Phase 1 trials represent a valuable treatment option. Herein we report the characteristics and outcomes of mCRC patients treated at our institution. Methods: We reviewed records of pts with mCRC enrolled on phase I trials at our institution from January 1999 to December 2016. Treatment-related response, toxicity, and deaths were recorded. Prognostic factors for overall survival (OS) were calculated using univariate (UVA) and multivariable Cox PH analysis (MVA). Results: We observed 187 enrollments with 152 unique patients accrued on 37 phase I trials. Median age was 59 years (range 29-83) and median number of prior therapies was 3 (range 0-8). 144 patients were evaluable for response. The clinical benefit rate (SD+response, CBR) was 33.2% and the ORR was 4.3%. Grade 3/4 non-hematological and hematological AE were seen in 25.5% and 17.3% of patients, respectively. Treatment-related mortality was 0.5%. Median PFS was 1.7 mos and OS was 8.2 mos. In UVA, the following variables predicted a shorter OS: age (p = 0.049); PS > 1 (p < 0.01); sites of metastases > 2 (p = 0.04); LDH > ULN (p < 0.001); albumin < 3.5 (p < 0.001); direct bilirubin > ULN (p = 0.02); WBC > 5.2 (p = 0.001); anemia (p = 0.046). In MVA, age > 60 (HR 1.63, p < 0.004), albumin < 3.5 (HR 3.69, p < 0.001), direct bilirubin > ULN (HR1.69, p < 0.01), and WBC > 5.2 (HR 1.97, p < 0.001) were negative prognostic factors for OS, adjusted for race and sex. A risk score based on MVA revealed that patients with a score of 0-1 had an improved OS (12.5mos) compared to a score of 2 (9.1mos, p-value < 0.005) and 3 (3.2 mos, p-value < 0.001). Conclusions: Patients with mCRC enrolled on phase 1 trials had a CBR of 33.2% and median OS of 8.2 mos, which exceeds third line therapies including regorafenib and trifluridine/tipiracil. Negative prognostic factors for OS were: age > 60, albumin < 3.5, direct bilirubin > ULN, and WBC > 5.2. A risk score based on these parameters showed that patients with a higher score had a significantly shorter OS, which may be useful in selecting patients for phase 1 trials.
12
Saouli, Zoi, Athanasios Papadopoulos, Georgia Kaiafa, Fotios Girtovitis, Georg Charisopoulos, Zisis Kontoninas, Anestis Zantidis e Charalambos Andreadis. "Tumor Marker CA 15-3 in Hematological Malignancies." Blood 108, n. 11 (16 novembre 2006): 4329. http://dx.doi.org/10.1182/blood.v108.11.4329.4329.
Abstract (sommario):
Abstract Introduction: CA 15-3 is a glycoprotein expressed in several adenocarcinomas, especially of the breast. It is used to detect recurrent or metastatic disease. Elevated levels can also be found in adenocarcinomas of the ovary, lung, pancreas, and colon, and are also related to benign breast or ovarian disease, endometriosis, hepatitis, pregnancy and lactation. To our knowledge with the exception of multiple myeloma, there are no references for the significance of the CA 15-3 in hematological malignancies. Aim of our study was to evaluate the levels of CA 15-3 in patients with various hematological malignancies. Material and Methods: 84 patients with hematological malignancies were tested: MDS 27 pts, non Hodgkin lymphoma 12 pts, Hodgkin’s lymphoma 3 pts, chronic lymphocytic leukemia 13 pts, acute leukemia: 7 pts, multiple myeloma 8 pts, chronic myeloid leukemia 3 pts and other chronic myeloproliferative disorders 11 pts. 55% of the patients were men with average age of 55 (17–87) and 45% were women with average age of 52 (35–64). A group of 45 healthy volunteers’ blood donors was also tested. Immunoradiometric assay (IRMA) has been used to determine the circulating levels of the CA 15-3 marker. Results: None of the healthy volunteers had elevated Ca 15-3 levels. Among the 84 patients, 31 (36,9%) had elevated levels of CA 15-3. In MDS 10/27 pts, in Non Hodgkin Lymphoma 5/12 pts, in Hodgkin Lymphoma 1/3 pts, in Chronic Lymphocytic Leukemia 5/13 pts, in Multiple Myeloma 4/8 pts, in acute leukemia 1/7 pts and in other myeloproliferative disorders 4/11 pts. The CA 15-3 levels in hematological patients were higher than the ones in the healthy group. The difference was statistically significant (p <0.0001), (Table 1). 31 patients who where either untreated or had recurrent disease (subgroup a), had elevated CA 15-3 levels (36,8 ± 8,9 U/ml) while the rest 53 patients who were under therapy or were in remission (subgroup b) had normal levels (14,3 ± 5,2 U/ml). A statistically significant difference between the two subgroups was observed, (p <0.0001), (Table 2). The low risk MDS patients (RA, RARS) had normal level of CA 15-3, while the high risk MDS patients (RAEB, RAEB-t, CMML) had high levels of CA 15-3. Conclusions: CA 15-3 can be an indicative marker of the activity of a hematological malignancy. Also, it might be of value in monitoring hematological diseases and response to therapy. Table 1 Ca 15-3 (U/ml) Patients (total, n=84) 23 ± 12,3 Normal Subjects (n=45) 14,1 ± 4,6 p < 0.0001 Table 2 Ca 15-3 (U/ml) Subgroup a 36,8 ± 8,9 Subgroup b 14,3 ± 5,2 p < 0.0001
13
Thamotharan, Shanthie, Nupur Raychaudhuri, Masatoshi Tomi, Bo-Chul Shin e Sherin U. Devaskar. "Hypoxic adaptation engages the CBP/CREST-induced coactivator complex of Creb-HIF-1α in transactivating murine neuroblastic glucose transporter". American Journal of Physiology-Endocrinology and Metabolism 304, n. 6 (15 marzo 2013): E583—E598. http://dx.doi.org/10.1152/ajpendo.00513.2012.
Abstract (sommario):
We have shown in vitro a hypoxia-induced time-dependent increase in facilitative glucose transporter isoform 3 (GLUT3) expression in N2A murine neuroblasts. This increase in GLUT3 expression is partially reliant on a transcriptional increase noted in actinomycin D and cycloheximide pretreatment experiments. Transient transfection assays in N2A neuroblasts using murine glut3-luciferase reporter constructs mapped the hypoxia-induced enhancer activities to −857- to −573-bp and −203- to −177-bp regions. Hypoxia-exposed N2A nuclear extracts demonstrated an increase in HIF-1α and p-Creb binding to HRE (−828 to −824 bp) and AP-1 (−187 to −180 bp) cis-elements, respectively, in electromobility shift and supershift assays, which was confirmed by chromatin immunoprecipitation assays. In addition, the interaction of CBP with Creb and HIF-1α and CREST with CBP in hypoxia was detected by coimmunoprecipitation. Furthermore, small interference (si)RNA targeting Creb in these cells decreased endogenous Creb concentrations that reduced by twofold hypoxia-induced glut3 gene transcription. Thus, in N2A neuroblasts, phosphorylated HIF-1α and Creb mediated the hypoxia-induced increase in glut3 transcription. Coactivation by the Ca++-dependent CREST and CBP proteins may enhance cross-talk between p-Creb-AP-1 and HIF-1α/HRE of the glut3 gene. Collectively, these processes can facilitate an adaptive response to hypoxic energy depletion targeted at enhancing glucose transport and minimizing injury while fueling the proliferative potential of neuroblasts.
14
Favorito, Scarlett Aldo de Souza, Elisabete Alerico Gonçalves e Paulo Vitor Teodoro. "História e Filosofia da Ciência: investigação documental para a formação de professores de ciências". Conjecturas 22, n. 1 (26 gennaio 2022): 865–79. http://dx.doi.org/10.53660/conj-522-821.
Abstract (sommario):
A pesquisa objetivou-se promover uma análise nos Currículos dos Campis de uma Instituição de Ensino Superior (IES) os quais possuem Cursos de Licenciatura em Química/Ciências, verificando a existência e relevância das disciplinas que aborda a História e Filosofia das Ciências (HFC). A pesquisa desenvolvida é de cunho qualitativo, com investigação documental. Como fundamentação teórica, utilizou-se a pesquisa bibliográfica. Os procedimentos metodológicos dividiu a pesquisa em quatro etapas, sendo: 1) Levantamento dos Campis da IES que possuem o curso de Licenciatura em Química; 2) Solicitação, aos Coordenadores, da autorização para a realização da pesquisa e disponibilização dos Projetos Pedagógicos dos Cursos (PPCs); 3) Análise e verificação da existência e relevância das disciplinas de HFC na Matriz Curricular; 4) Elaboração e envio de questionário por meio da plataforma do Google, para os professores dos campis da IES. Depois da análise, concluímos que os cursos possuem escassas disciplinas efetivamente voltadas a HFC, e que os docentes não foram preparados em suas graduações. Além disso, mesmo os que já trabalharam com a HFC, sentem dificuldades em ministrá-las. Percebeu-se que é emergente a necessidade de repensar os currículos, melhorando a concepção e relevância sobre as disciplinas de HFC a fim de promover melhor preparo dos futuros docentes.
15
Lázaro-Martínez, José Luis, Francisco Javier Aragón-Sánchez, Juan Vicente Beneit-Montesinos, Maximo A. González-Jurado, Esther García Morales e David Martínez Hernández. "Foot Biomechanics in Patients with Diabetes Mellitus". Journal of the American Podiatric Medical Association 101, n. 3 (1 maggio 2011): 208–14. http://dx.doi.org/10.7547/1010208.
Abstract (sommario):
Background: We sought to identify the biomechanical characteristics of the feet of patients with diabetes mellitus and the interrelationship with diabetic neuropathy by determining the range of joint mobility and the presence and locations of calluses and foot deformities. Methods: This observational comparative study involved 281 patients with diabetes mellitus who underwent neurologic and vascular examinations. Joint mobility studies were performed, and deformities and hyperkeratosis locations were assessed. Results: No substantial differences were found between patients with and without neuropathy in joint mobility range. Neuropathy was seen as a risk factor only in the passive range of motion of the first metatarsophalangeal joint (mean ± SD: 57.2° ± 19.5° versus 50.3° ± 22.5°, P = .008). Mean ± SD ankle joint mobility values were similar in both groups (83.0° ± 5.2° versus 82.8° ± 9.3°, P = .826). Patients without neuropathy had a higher rate of foot deformities such as hallux abductus valgus and hammer toes. There was also a higher presence of calluses in patients without neuropathy (82.8% versus 72.6%; P = .039). Conclusions: Diabetic neuropathy was not related to limited joint mobility and the presence of calluses. Patients with neuropathy did not show a higher risk of any of the deformities examined. These findings suggest that the etiology of biomechanical alterations in diabetic people is complex and may involve several anatomically and pathologically predisposing factors. (J Am Podiatr Med Assoc 101(3): 208–214, 2011)
16
Zhelyazkov, Ivan, Ramesh Chandra e Abhishek K. Srivastava. "Modeling Kelvin–Helmholtz Instability in Soft X-Ray Solar Jets". Advances in Astronomy 2017 (2017): 1–18. http://dx.doi.org/10.1155/2017/2626495.
Abstract (sommario):
Development of Kelvin–Helmholtz (KH) instability in solar coronal jets can trigger the wave turbulence considered as one of the main mechanisms of coronal heating. In this review, we have investigated the propagation of normal MHD modes running on three X-ray jets modeling them as untwisted and slightly twisted moving cylindrical flux tubes. The basic physical parameters of the jets are temperatures in the range of 5.2–8.2 MK, particle number densities of the order of109 cm−3, and speeds of 385, 437, and 532 km s−1, respectively. For small density contrast between the environment and a given jet, as well as at ambient coronal temperature of 2.0 MK and magnetic field around 7 G, we have obtained that the kink (m=1) mode propagating on moving untwisted flux tubes can become unstable in the first and second jets at flow speeds of≅348 and 429 km s−1, respectively. The KH instability onset in the third jet requires a speed of≅826 km s−1, higher than the observed one. The same mode, propagating in weakly twisted flux tubes, becomes unstable at flow speeds of≅361 km s−1for the first and of 443 km s−1for the second jet. Except the kink mode, the twisted moving flux tube supports the propagation of higher (m>1) MHD modes that can become unstable at accessible jets’ speeds.
17
Wang, Lei, Zheng Wu, Qian He, Yiting Li, Subin Wang, Feiping Li, Hui Wang, Wenhui Li e Yaqian Han. "Distribution pattern of metastatic lymph nodes in 870 cases of nasopharyngeal carcinoma: A clue for individualized elective prophylactic neck irradiation." Journal of Clinical Oncology 41, n. 16_suppl (1 giugno 2023): e18049-e18049. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e18049.
Abstract (sommario):
e18049 Background: We aimed to explore a potential individualized elective prophylactic neck irradiation (iEPNI) to optimize the current strategy by investigating the distribution of metastatic lymph nodes (LNs) in nasopharyngeal carcinoma (NPC). Methods: Magnetic resonance imaging (MRI) and clinical data of 870 non-distant metastatic NPC patients admitted to the Hunan Cancer Hospital between January 2019 and December 2019 were reviewed. All patients were staged using the 8th TNM staging system, and the LNs location was assigned based on the 2013 guidelines. According to the distribution patterns of the LNs in NPC, the intra-regional lymphatic drainage levels were categorized into the following three stations: Station 1st of level VIIa and II; Station 2nd of level III and Va; and Station 3rd of level IV, Vb, and Vc. Other levels were defined as extra-regional areas. Results: The incidence of LNs metastasis was 822/870 (94.5%), including 198 cases of unilateral metastasis and 624 cases of bilateral metastasis. Among the 870 patients, the most frequently involved intra-regional lymphatic drainage was level IIb (87.1%), followed by level VIIa (80.0%), IIa (61.8%), Va (30.6%), IV (21.4%), Vb (8.9%), and Vc (1.1%). In the extra-regional areas, the detailed LNs distribution was: level Ia (0.2%), level Ib (7.7%), level VI (0.1%), level VIIb (5.6%), level VIII (5.5%), level IX (0.3%), and level X (0.2%). The rates of LNs metastasis in Station 1st, Station 2nd, and Station 3rd were 820/870 (94.3%), 532/870 (61.1%), and 199/870 (22.9%), respectively. Only 4 patients were considered to be skipping metastasis among the three stations (4/870, 0.5%). Additionally, in 203 patients with unilateral Station 1st LNs metastasis, there were 86 (42.4%) and 37 (18.2%) patients with ipsilateral Station 2nd and Station 3rd metastasis, respectively, and 3 (1.5%) and 1 (0.5%) patients with contralateral Station 2nd and Station 3rd LNs metastasis, respectively. Conclusions: LNs spread from Station 1st to Station 3rd successively with rare skipping metastasis. A potential iEPNI strategy of prophylactical neck irradiation to the ipsilateral latter node-negative station might be feasible, which is detailed as follows: irradiation to Station 1st in patients with no LNs metastasis, irradiation to Station 2nd in patients with only Station 1st metastasis, and irradiation to Station 3rd in patients with Station 2nd metastasis but without Station 3rd metastasis. Further prospective investigations are expected to validate the strategy.
18
Wang, Bo, Huan Yang, Liqin Shen, Ji Wang, Wangyang Pu, Zhigang Chen, Xudong Shen, Jinxiang Fu e Zhixiang Zhuang. "Rs56288038 (C/G) in 3'UTR of IRF-1 Regulated by MiR-502-5p Promotes Gastric Cancer Development". Cellular Physiology and Biochemistry 40, n. 1-2 (2016): 391–99. http://dx.doi.org/10.1159/000452554.
Abstract (sommario):
Background/Aims: Interferon regulatory factor 1 (IRF-1) has been shown to function as a transcriptional activator or repressor of a variety of target genes. However, its upstream, non-coding RNA-related regulatory capacity remains unknown. In this study, we focus on the miRNA-associated single nucleotide polymorphisms (SNPs) in the 3′untranslated region (UTR) of IRF-1 to further investigate the functional relationship and potential diagnostic value of the SNPs and miRNAs among Chinese gastric cancer (GC) patients. Methods: We performed a case-control study with 819 GC patients and 756 cancer-free controls. Genotyping by realtime PCR assay, cell transfection, and the dual luciferase reporter assay were used in our study, and the 5-year overall survival rate and relapse-free survival rate in different groups were investigated. Results: We found that patients suffering from Helicobacter pylori (Hp) infection were the susceptible population compared to controls. SNP rs56288038 (C/G) in IRF-1 3′UTR was involved in the occurrence of GC by acting as a tumor promoter factor. SNP rs56288038 (C/G) could be up-regulated by miR-502-5p, which caused a down-regulation of IRF-1 in cell lines and decreased apoptosis induced by IFN-γ. Carrying the G genotype was related to significantly low expression of IRF-1 and Hp infection, poor differentiation, big tumor size, invasion depth, as well as the high probability of metastasis, and moreover, the C/G SNP was associated with shorter survival of GC patients with five years of follow-up study. Conclusions: our findings have shown that the SNP rs56288038 (C/G) in IRF-1 3′UTR acted as a promotion factor in GC development through enhancing the regulatory role of miR-502-5p in IRF-1 expression.
19
Melnick, David, Akash Jain, Vikas Gupta e Katherine Sulham. "1684. Hospital Costs and Reimbursement in Patients with Resistant Enterobacteriaceae (ENT) Urinary Tract Infection (UTI) in the United States (US): A Multicenter Analysis". Open Forum Infectious Diseases 7, Supplement_1 (1 ottobre 2020): S826. http://dx.doi.org/10.1093/ofid/ofaa439.1862.
Abstract (sommario):
Abstract Background Rates of fluoroquinolone resistance (FQ-R) and third-generation cephalosporin resistance/extended-spectrum beta-lactamases (ESBL+) are rising. These pathogens generally retain susceptibility to intravenous (IV) carbapenems; however, the loss of susceptibility to commonly used oral (PO) antibiotics limits the opportunity to transition these patients home, leading to increased length of stay (LOS) and higher costs. Here, we evaluate the hospital LOS, costs and reimbursement for UTI hospitalizations. Methods We analyzed the first positive enterobacteriaceae (ENT) urine culture ≤ 3 days from hospital admission in patients with a primary or secondary UTI ICD10 discharge diagnosis from 68 US hospitals admitted October 1, 2015-2017. Patient characteristics and outcomes were categorized by ESBL+ and FQ-R status. IV to PO was identified as PO therapy after 24 hours of IV. Outcomes were stratified by resistance and PO conversion status. Results 16,022 patients were eligible for analysis; 5,017 (31.3%) were FQ-R, 1,763 (11.0%) were ESBL+, and 1,433 (8.9%) were both FQ-R and ESBL+; 2,367 (14.8%) were converted to PO antibiotics during their hospitalization. Overall, mean LOS, costs, and reimbursement were 5.2 days, $9,303 and $8,501 (mean difference between cost and reimbursement: -$878). Mean LOS was shorter and mean difference between cost and reimbursement was lower overall for patients converted to PO therapy vs. those who did not (4.7 vs. 5.3 days, -$532 vs. -$938). Drug resistance was associated with higher LOS and a larger difference between cost and reimbursement; patients who were FQ-R and ESBL+ and did not convert to PO had a mean LOS of 6.0 days, costs of $11,482, and reimbursement of $9,243 (difference: -$2,446). Mean LOS, costs, and reimbursement for patients who were neither FQ-R nor ESBL+ and who did convert to PO therapy were 4.6 days, $7,904, and $7,496 (difference: -$527), respectively. Conclusion Reduced LOS and substantial cost savings could be recognized by efficiently converting patients receiving IV antimicrobials to PO and discharging them from the hospital. Lack of PO therapies with activity against resistant pathogens has made this challenging; new PO options may help reduce hospital costs and resources required to treat these UTI patients. Disclosures David Melnick, MD, Spero Therapeutics (Employee)Spero Therapeutics (Employee) Akash Jain, PhD, Spero Therapeutics (Employee) Vikas Gupta, PharmD, BCPS, Becton, Dickinson and Company (Employee, Shareholder)GlaxoSmithKline plc. (Other Financial or Material Support, Funding) Katherine Sulham, MPH, Spero Therapeutics (Independent Contractor)
20
Pulito-Cueto, V., F. Genre Romero, S. Remuzgo Martinez, B. Sevilla, N. Ortego, M. Leonardo, A. Peñalba et al. "AB0166 IGAV AND IGAN: A SINGLE ENTITY REGARDING CD40, BLK AND BANK1 POLYMORPHISMS". Annals of the Rheumatic Diseases 82, Suppl 1 (30 maggio 2023): 1263.2–1264. http://dx.doi.org/10.1136/annrheumdis-2023-eular.81.
Abstract (sommario):
BackgroundIgA vasculitis (IgAV) and IgA nephropathy (IgAN) are inflammatory conditions that share pathophysiological mechanisms, being B-cells crucial players in both diseases [1]. In this regard, some authors have suggested that IgAV and IgAN may represent different outcomes of a continuous spectrum of a disease [2]. In addition,CD40, BLKandBANK1are relevant genes involved in the development and signalling of B-cells and are also identified as susceptibilitylocifor several immune-mediated diseases [3-6].ObjectivesTo determine whether IgAV and IgAN may be different outcomes of a single disease, by assessing theCD40, BLKandBANK1genetic pattern.MethodsThree genetic variants withinCD40(rs1883832, rs1535045, rs4813003), three genetic polymorphisms withinBLK(rs2254546, rs2736340, rs2618476) as well as twoBANK1genetic variants (rs10516487, rs3733197) were genotyped in 380 Caucasian patients diagnosed with IgAV, 90 patients diagnosed with IgAN and 1,012 ethnically matched healthy controls. The eight polymorphisms selected were previously associated with several inflammatory diseases [3-6].ResultsSimilar genotype and allele frequencies were observed in IgAV patients when compared to those with IgAN, whenCD40, BLKandBANK1variants were analyzed independently (Table 1). In addition, no statistically significant differences were observed between patients with IgAV and healthy controls as well as between patients with IgAN and healthy controls, whenCD40, BLKandBANK1genetic variants were analyzed independently (Table 1). Similar results were disclosed when haplotype frequencies ofCD40, BLKandBANK1were compared between patients with IgAV and those with IgAN, as well as between patients with IgAV and healthy controls and between IgAN and healthy controls.ConclusionOur results reveal a similarCD40, BLKandBANK1genetic distribution in IgAV and IgAN, supporting that IgAV and IgAN may represent different outcomes of a single disease.References[1] N Engl J Med 2013;368:2402-14;[2] Am J Kidney Dis 1988;12:373-7;[3] Nat Genet 2009;41:824-8;[4] Ann Rheum Dis 2012;71:136-42;[5] Nat Genet 2012;44:517-21;[6] Nat Genet 2012;44:522-5.Table 1.Genotype and allele frequencies ofCD40, BLKandBANK1in patients with IgAV, patients with IgAN and healthy controls.ChangeGenotypes, % (n)Alleles, % (n)Polymorphism1/2Data set1/11/22/212CD40rs1883832C/TIgAV54.0 (204)37.0 (140)9.0 (34)72.5 (548)27.5 (208)IgAN56.5 (48)36.5 (31)7.0 (6)74.7 (127)25.3 (43)Healthy controls52.9 (532)40.4 (409)6.7 (68)73.1 (1,479)26.9 (545)CD40rs1535045C/TIgAV53.6 (200)39.4 (147)7.0 (26)73.3 (547)26.7 (199)IgAN51.8 (44)41.2 (35)7.1 (6)72.4 (123)27.6 (47)Healthy controls56.7 (574)36.2 (366)7.1 (72)74.8 (1,514)25.2 (510)CD40rs4813003C/TIgAV78.0 (291)20.1 (75)1.9 (7)88.1 (657)11.9 (89)IgAN76.6 (59)20.8 (16)2.6 (2)87.0 (134)13.0 (20)Healthy controls74.9 (758)22.7 (230)2.4 (24)86.3 (1,746)13.7 (278)BLKrs2254546G/AIgAV74.5 (278)22.3 (83)3.2 (12)85.7 (639)14.3 (107)IgAN64.7 (55)31.8 (27)3.5 (3)80.6 (137)19.4 (33)Healthy controls71.3 (722)26.8 (271)1.9 (19)84.7 (1,715)15.3 (309)BLKrs2736340C/TIgAV62.8 (236)31.9 (120)5.3 (20)78.7 (592)21.3 (160)IgAN67.5 (52)31.2 (24)1.3 (1)83.1 (128)16.9 (26)Healthy controls59.9 (606)35.8 (362)4.3 (44)77.8 (1,574)22.2 (450)BLKrs2618476T/CIgAV60.2 (227)34.2 (129)5.6 (21)77.3 (583)22.7 (171)IgAN68.2 (58)24.7 (21)7.1 (6)80.6 (137)19.4 (33)Healthy controls57.9 (586)37.3 (377)4.8 (49)76.5 (1,549)23.5 (475)BANK1rs10516487G/AIgAV52.8 (200)39.8 (151)7.4 (28)72.7 (551)27.3 (207)IgAN50.6 (42)38.6 (32)10.8 (9)69.9 (116)30.1 (50)Healthy controls50.8 (514)41.8 (423)7.4 (75)71.7 (1,451)28.3 (573)BANK1rs3733197G/AIgAV50.0 (187)39.0 (146)11.0 (41)69.5 (520)30.5 (228)IgAN47.1 (40)37.6 (32)15.3 (13)65.9 (112)34.1 (58)Healthy controls49.5 (501)41.6 (421)8.9 (90)70.3 (1,423)29.7 (601)AcknowledgementsThis study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI18/00042 and PI21/00042, co-funded by European Regional Development Fund (ERDF), `Investing in your future´; VP-C: PI18/00042 from ISCIII, co-funded by ERDF; MSM-G is supported by funds of TRANSVAL22/01 from IDIVAL; RL-M: Miguel Servet type II programme fellowship from the ISCIII, co-funded by the European Social Fund (`Investing in your future´) [CPII21/00004].Disclosure of InterestsVerónica Pulito-Cueto: None declared, Fernanda Genre Romero: None declared, Sara Remuzgo Martinez: None declared, Belén Sevilla: None declared, Norberto Ortego: None declared, Maite Leonardo: None declared, Ana Peñalba: None declared, J. Narváez: None declared, Luis Martín-Penagos: None declared, Lara Belmar-Vega: None declared, Cristina Gomez-Fernandez: None declared, María Sebastián Mora-Gil: None declared, LUIS CAMINAL MONTERO: None declared, PAZ COLLADO: None declared, Antonio Fernandez-Nebro: None declared, Gisela Diaz-Cordobes: None declared, Secundino Cigarrán: None declared, Jesús Calviño: None declared, Carmen Cobelo: None declared, Diego de Argila: None declared, Javier Sanchez Perez: None declared, Miren Uriarte-Ecenarro: None declared, Esteban Rubio-Romero: None declared, MANUEL LEON LUQUE: None declared, Juan María Blanco-Madrigal: None declared, E. Galíndez-Agirregoikoa: None declared, Javier Martin Ibanez: None declared, Santos Castañeda: None declared, Miguel A González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi, Lilly, Celgene, MSD and GSK, Grant/research support from: Abbvie, MSD, Jansen and Roche, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Raquel López-Mejías: None declared.
21
Aulia Annisa, Arni Rizqiani Rusydi e Ella Andayanie. "Gambaran Penerapan Protokol Kesehatan Di Kantor Kelurahan Benteng Kabupaten Wajo". Window of Public Health Journal 3, n. 6 (30 dicembre 2022): 1169–76. http://dx.doi.org/10.33096/woph.v3i6.48.
Abstract (sommario):
Coronavirus adalah virus jenis baru yang telah berhasil menginfeksi ribuan juta masyarakat global dalam waktu yang sangat singkat. Berdasarkan data pantauan Covid-19 di kecamatan pitumpanua yaitu terdiri dari 190 orang yaitu isolasi 10 orang, dirawat 0 orang, sembuh 177 orang dan meninggal 3 orang. Jenis penelitian yang digunakan adalah menggunakan metode kuantitatif dengan pendekatan deskriptif dan menggunakan skala likert. Dengan sampel sebanyak 35 orang dengan secara Accidental sampling. Hasil penelitian berdasarkan aspek penggunaan masker pelindung wajah tergolong baik sebanyak 25 masyarakat (71,4%), aspek mencuci tangan tergolong baik sebanyak 29 masyarakat sebanyak (82,9%), aspek penggunaan hand sanitizer tergolong cukup baik sebanyak 19 masyarakat (54,3%), aspek jaga jarak tergolong cukup baik sebanyak 20 masyarakat (57,2%), aspek etika batuk dan bersin tergolong baik sebanyak 29 masyarakat (82,9%), aspek isolasi mandiri tergolong baik sebanyak 22 masyarakat (62,9%) dan aspek menjaga kesehatan tergolong baik sebanyak 24 masyarakat (68,6%). Adapun saran yang ingin disampaikan peneliti yaitu diharapkan tetap mengikuti protokol kesehatan pencegahan virus corona kepada masyarakat dan instansi saat melakukan pelayanan.
22
Hamdan, Sinin, Md Rezaur Rahman, Khairul Anwar Mohamad Said, Ana Sakura Zainal Abidin e Ahmad Fauzi Musib. "Sompoton: Sabah bamboo mouth organ". BioResources 17, n. 3 (29 luglio 2022): 5335–48. http://dx.doi.org/10.15376/biores.17.3.5335-5348.
Abstract (sommario):
This study considered the Sabah traditional bamboo musical instrument, sompoton. The fast Fourier transform (FFT) of sompoton was determined via a Pico oscilloscope. All three sompotons displayed almost similar fundamental frequencies. The individual tubes 1, 2, 3, 4, 5, 6, and 8 (except tube 7) of sompoton I, II, and III produced the fundamental frequency (in hertz) as 924, 758, 655, 589, 449, 407, 537, as 954, 779, 655, 614, 469, 387, 552, and as 944, 820, 655, 635, 407, 407, and 552, respectively. The averaged frequency obtained from the three sompotons (with the diatonic frequency and note in bracket) was 940.6 (932.3-A5# tube 1), 785.6 (783.9-G5 tube 2), 655 (659.2-E5 tube 3), 612.6 (622.2-D5# tube 4), 547 (554.3-C5# tube 8), 441.6 (440-A4 tube 5), and 400.3 (392-G4 tube 6). The tunings were remarkably similar in the tonal relationships. The pitch of the drone tube (tube 6) repeated an octave higher at tube 2, the intervals of perfect 4th higher at tube 8, and the intervals of perfect 5th higher at tube 4 were always found. The standard deviations of the fundamental pitch from the three sompotons for tube 1, 2, 3, 4, 5, 6, and 8 were 15.3, 31.5, 0.0, 9.2, 31.6, 11.5, and 8.7, respectively.
23
Wong, Judith JM, Christoph P. Hornik, Yee Hui Mok, Tsee Foong Loh e Jan Hau Lee. "Performance of the Paediatric Index of Mortality 3 and Paediatric Logistic Organ Dysfunction 2 Scores in Critically Ill Children". Annals of the Academy of Medicine, Singapore 47, n. 8 (15 agosto 2018): 285–90. http://dx.doi.org/10.47102/annals-acadmedsg.v47n8p285.
Abstract (sommario):
Introduction: The Paediatric Index of Mortality 3 (PIM 3) and Paediatric Logistic Organ Dysfunction 2 (PELOD 2) scores were recently revised. We aimed to assess the performance of these scores in a contemporary cohort of critically ill children. Materials and Methods: This is a single-centre prospective study conducted in a multidisciplinary paediatric intensive care unit (PICU). Consecutive PICU admissions over 1 year were included and admission PIM 3 and PELOD 2 scores were calculated. The performance of each of the scores was evaluated by calculating the area under the curve (AUC) of the receiver operating characteristic (ROC) and the Hosmer-Lemeshow goodness-of-fit test for the outcome of PICU mortality. Results: A total of 570 patient admissions were eligible for this study. The median age of patients was 3.1 (interquartile range [IQR]: 0.4, 8.9 years). Overall median PIM 3 and PELOD 2 scores were 1.2 (IQR: 0.4, 3.2) % and 4 (IQR: 2, 7), respectively. The overall mortality rate was 35/570 (6.1%). The PIM 3 and PELOD 2 scores had good discrimination for mortality (AUCs 0.88 [95% confidence interval (CI) 0.85, 0.91] and 0.86 [95% CI 0.83, 0.89], respectively). Goodness-of-fit was satisfactory for both scores. Higher PIM 3 and PELOD 2 scores were also associated with decreasing ventilator and PICU-free days. Conclusion: PIM 3 and PELOD 2 scores are robust severity of illness scores that are generalisable to a contemporary cohort of critically ill children in Singapore. Key words: Multiple organ dysfunction syndrome, Paediatric intensive care unit, Patient outcome assessment, Severity of illness index
24
CHOUBEY, A., S. SOM, R. KUMARI e S. K. SHARMA. "STUDIES ON OPTOELECTRONIC PROPERTIES OF Eu3+ ACTIVATED LaOCl NANOPHOSPHOR". Modern Physics Letters B 25, n. 09 (10 aprile 2011): 685–96. http://dx.doi.org/10.1142/s021798491102595x.
Abstract (sommario):
The 0.1 mol% europium ( Eu 3+) activated lanthanum oxychloride nanophosphor was prepared by the liquid-phase method. The X-ray diffraction analysis of the prepared compound exhibits the tetragonal structure having the particles size in the range of 18–21 nm. The band gap of Eu 3+ doped LaOCl phosphor was found to be around 5.2 eV using absorption and diffuse reflectance measurements. The photoluminescence (PL) emission spectra show the bright emission in orange–red region from 580 nm to 630 nm. The most intense emission peak at 621 nm was due to transition in energy levels 5 D 0 → 7 F 2 of Eu 3+ ions. The absorption and stimulated emission cross-section of the intense peak were found to be 4.135 × 10-20 cm2 and 8.9 × 10-20 cm2 respectively. The wide band gap and high stimulated emission cross-section of prepared nanophosphor makes its possible applications as red emitting phosphor in display devices and laser system.
25
Moehler, Markus Hermann, Gunnar Folprecht, Volker Heinemann, Julian Holch, Annett Maderer, Stefan Kasper, Susanna Hegewisch-Becker et al. "Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3)." Journal of Clinical Oncology 37, n. 4_suppl (1 febbraio 2019): 571. http://dx.doi.org/10.1200/jco.2019.37.4_suppl.571.
Abstract (sommario):
571 Background: Metastatic colorectal cancer (mCRC) patients (pts) with liver-limited disease (LLD) have a chance of long-term overall survival (OS) and potential cure after complete hepatic metastasectomy. The appropriate postoperative treatment strategy is still controversial. L-BLP25 as antigen-specific cancer vaccine targeting mucin 1 (MUC1) was recently evaluated as adjuvant therapy in mCRC pts after R0/R1 LLD resection (LICC trial, NCT01462513). Here we compared the LICC surveillance program and efficacy results for secondarily resected LLD pts versus historical controls, i.e. the CELIM trial (Folprecht et al, Ann Oncol 2014) of potentially resectable LLD mCRC pts and a FIRE-3-LLD subgroup (Holch et al, Int J Cancer 2018). Methods: LICC, CELIM and FIRE-3-LLD subgroup pts with stage IV mCRC limited to liver metastases who underwent hepatic resection (R0 or R1) were compared regarding pts characteristics, surveillance and efficacy outcome. LICC pts received adjuvant L-BLP25 or placebo after secondary LLD resection as 8 weekly doses, followed by 6 week maintenance intervals and tight surveillance until recurrence or a maximum of 2 years. Results: In LICC, 41/121 pts (33.9%) were secondarily resected, and R0 resection was achieved in 31 pts (75.6%). In CELIM, 36/106 pts (34%) with primary unresectable LLD were secondarily R0 resected. In FIRE-3-LLD, secondary resection was feasible for 29/133 pts (21.8%). After R0 resection, median recurrence free survival (mRFS) was 8.9 months in LICC, 9.9 months in CELIM and 11.5/12.4 months in FIRE-3-LLD in either treatment arm. In the LICC trial, median overall survival (mOS) in secondarily resected pts was 65.1 months, with 38.3 months for the R1 and is not yet reached for the R0 subgroup. In CELIM, mOS was 53.9 months for R0 resected pts. In FIRE-3-LLD, after secondary resection mOS was 56.2 months. Median age was about 5 years less in LICC. Further details will be presented. Conclusions: Secondary resected pts of LICC, CELIM and FIRE-3 showed impressive median OS with better OS for LICC and a younger patient cohort. The established tight LICC surveillance program after surgery might have had a positive impact on survival. Clinical trial information: LICC: NCT01462513; FIRE-3: NCT00433927; CELIM: NCT00153998.
26
Dougados, M., U. Kiltz, A. Kivitz, K. Pavelka, S. Rohrer, S. Mccreddin, E. Quebe-Fehling, B. Porter e Z. Talloczy. "THU0374 NONSTEROIDAL ANTI-INFLAMMATORY DRUG-SPARING EFFECT OF SECUKINUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 4-YEAR RESULTS FROM THE MEASURE 2, 3 AND 4 PHASE 3 TRIALS". Annals of the Rheumatic Diseases 79, Suppl 1 (giugno 2020): 419–20. http://dx.doi.org/10.1136/annrheumdis-2020-eular.824.
Abstract (sommario):
Background:Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in reducing pain and stiffness in ankylosing spondylitis (AS) patients (pts).1However, continuous use of NSAIDs may lead to gastrointestinal, cardiovascular and renal toxicity.2Therefore, reduction in NSAID intake is desirable in AS pts.Objectives:To evaluate the long-term effect of secukinumab (SEC) on NSAID intake in AS pts pooled from the 3 SEC trials (MEASURE [M] 2-4).Methods:NSAID intake was evaluated prospectively using the Assessment of SpondyloArthritis International Society (ASAS)-NSAID score.3The score was determined by type of NSAID, daily dose, and weights from frequency of intake, as well as % of time use in period. An ASAS-NSAID score of ‘0’ indicates no NSAID intake. Pts with ASAS-NSAID score >0 at baseline (BL) were analysed. SEC dose groups were defined as Any 150 or 300 mg, as defined for pooled safety analyses for SEC. Pts with initial placebo treatment (up to 24 weeks) were included in their respective post-Week 24 SEC dose groups to analyse ASAS-NSAID score at Year (Y) 2 (M2-4), Y3 (M2-3) and Y4 (M2) from BL. From the ASAS-NSAID score at BL, the mean change in ASAS-NSAID score, proportion of pts achieving 50% reduction, and the proportion of pts with score <10 were evaluated for each dose at Y2, 3 and 4. Based on the distribution of ASAS-NSAID scores at BL, 2 subgroups were evaluated: (i) <75 (low user); (ii) ≥75 (high user).Results:Overall, 562 pts (SEC: 150 mg, N=467; 300 mg, N=95) were analysed. The mean ASAS-NSAID score decreased with time in both dose groups. Greater improvements were observed in high NSAID users and with longer treatment exposure (Figure). Proportion of pts who achieved 50% reduction in ASAS-NSAID score increased with time in both SEC 150 and 300 mg groups. Proportion of pts with clinically meaningful reduction of ASAS-NSAID score <10 increased with time in both dose groups and in both low and high NSAID users (Table).TableTime (years)NSAID intakeLow (<0 ASAS-NSAID <75)High (ASAS-NSAID ≥75)OverallSEC 150 mg(N=167)SEC 300 mg#(N=37)SEC 150 mg(N=300)SEC 300 mg#(N=58)SEC 150 mg(N=467)SEC 300 mg#(N=95)Proportion of pts who achieved 50% reduction from BL in ASAS-NSAID score, % (n/m)*225 (38/154)18 (6/33)19 (50/267)14 (7/49)21 (88/421)16 (13/82)323 (13/56)21 (7/33)26 (26/100)17 (8/46)25 (39/156)19 (15/79)429 (7/24)-26 (14/54)-27 (21/78)-Proportion of pts with ASAS-NSAID score <10,% (n/m)*239 (60/154)33 (11/33)12 (33/267)12 (6/49)22 (93/421)21 (17/82)334 (19/56)33 (11/33)17 (17/100)13 (6/46)23 (36/156)22 (17/79)438 (9/24)-20 (11/54)-26 (20/78)-*Observed data.#MEASURE 3 that evaluated 300 mg was only a 3 year study. N, total number of pts in the group; n, number of pts with response; m, number of evaluable ptsConclusion:SEC provided sustained improvement in ASAS-NSAID score in AS pts and was associated with clinically relevant NSAID-sparing effect in AS pts, when used to measure NSAID intake up to 4 years of treatment. Overall, SEC provided long-term NSAID-sparing effects in both high and low NSAID users.References:[1]Molto A, et al.Joint Bone Spine. 2017;84:79–82.[2]Dougados M, et al.Arthritis Res & Ther. 2014;16:481.[3]Dougados M, et al.Ann Rheum Dis. 2011;70:249–51.Disclosure of Interests:Maxime Dougados Grant/research support from: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Consultant of: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Speakers bureau: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Uta Kiltz Grant/research support from: AbbVie, Amgen, Biogen, Novartis, Pfizer, Consultant of: AbbVie, Biocad, Eli Lilly and Company, Grünenthal, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, MSD, Novartis, Pfizer, Roche, UCB, Alan Kivitz Shareholder of: AbbVie, Amgen, Gilead, GSK, Pfizer Inc, Sanofi, Consultant of: AbbVie, Boehringer Ingelheim,,Flexion, Genzyme, Gilead, Janssen, Novartis, Pfizer Inc, Regeneron, Sanofi, SUN Pharma Advanced Research, UCB, Paid instructor for: Celgene, Genzyme, Horizon, Merck, Novartis, Pfizer, Regeneron, Sanofi, Speakers bureau: AbbVie, Celgene, Flexion, Genzyme, Horizon, Merck, Novartis, Pfizer Inc, Regeneron, Sanofi, Karel Pavelka Speakers bureau: AbbVie, BMS, MSD, UCB, Medac, Egis, Pfizer, Roche, Biogen, Novartis, Susanne Rohrer Employee of: Novartis, Suzanne McCreddin Shareholder of: Novartis, Employee of: Novartis, Erhard Quebe-Fehling Shareholder of: Novartis, Employee of: Novartis, Brian Porter Shareholder of: Novartis, Employee of: Novartis, Zsolts Talloczy Shareholder of: Novartis, Employee of: Novartis
27
Jackson, Kelly, Mary Bachhuber, Dawn Bowden, Katherine Etter e Cindy Tong. "Comprehensive Hip Fracture Care Program: Successive Implementation in 3 Hospitals". Geriatric Orthopaedic Surgery & Rehabilitation 10 (1 gennaio 2019): 215145931984605. http://dx.doi.org/10.1177/2151459319846057.
Abstract (sommario):
Introduction: Hip fractures are common and costly in the elderly population, often contributing to loss of function and independence. Prompt, coordinated surgical care may improve clinical and economic outcomes for this population. Materials and Methods: We created an interdisciplinary care program focused on minimizing time spent immobilized awaiting surgery and streamlining the care pathway for hip fracture. Patients older than 65 years with any hip fracture type including hip fracture repair Diagnosis-Related Group codes (MS-DRG 480, 481, or 482) and MS-DRG 469 and 470 with a hip fracture diagnosis were included in the study. The Hip Fracture Care program (HFCP) was implemented on a staggered basis in 3 hospitals in the HonorHealth system. Time to surgery, length of stay, and discharge location (home/skilled nursing facility) were compared pre- and post-intervention, utilizing an interrupted time series analysis to account for background trends. Results: More than 2000 patients across the 3 facilities received HFCP care; demographics were similar for the 826 patients serving as the pre-implementation comparison group. Mean (standard deviation [SD]) length of stay decreased from 5.6 (4.0) to 4.7 (2.9) days (mean difference 0.9 days; P < .05). Mean (SD) time from admission to the operating room decreased from 30.8 (21.1) to 25.6 (20.5) hours (mean difference 5.2 hours; P < .05). There was no change in the proportion of patients discharged to home versus skilled nursing facility. Discussion: Optimal care of this vulnerable population can significantly reduce the time to surgery and length of stay. Conclusions: Length of stay was reduced by nearly 1 day with implementation of a multifactorial program for hip fracture care.
28
Bearss, Karolina A., e Joseph F. X. DeSouza. "Parkinson’s Disease Motor Symptom Progression Slowed with Multisensory Dance Learning over 3-Years: A Preliminary Longitudinal Investigation". Brain Sciences 11, n. 7 (7 luglio 2021): 895. http://dx.doi.org/10.3390/brainsci11070895.
Abstract (sommario):
Parkinson’s disease (PD) is a neurodegenerative disease that has a fast progression of motor dysfunction within the first 5 years of diagnosis, showing an annual motor rate of decline of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) between 5.2 and 8.9 points. We aimed to determine both motor and non-motor PD symptom progression while participating in dance classes once per week over a period of three years. Longitudinal data was assessed for a total of 32 people with PD using MDS-UPDRS scores. Daily motor rate of decline was zero (slope = 0.000146) in PD-Dancers, indicating no motor impairment, whereas the PD-Reference group showed the expected motor decline across three years (p < 0.01). Similarly, non-motor aspects of daily living, motor experiences of daily living, and motor complications showed no significant decline. A significant group (PD-Dancers and PD-Reference) by days interaction showed that PD who train once per week have less motor impairment (M = 18.75) than PD-References who do not train (M = 24.61) over time (p < 0.05). Training is effective at slowing both motor and non-motor PD symptoms over three years as shown in decreased scores of the MDS-UPDRS.
29
Palá-Paúl, Jesús, Lachlan M. Copeland, Joseph J. Brophy e Robert J. Goldsack. "Essential Oil Composition of two New Species of Phebalium (Rutaceae) from North-Eastern NSW, Australia". Natural Product Communications 4, n. 7 (luglio 2009): 1934578X0900400. http://dx.doi.org/10.1177/1934578x0900400722.
Abstract (sommario):
The composition of the essential oil steam distilled with cohobation from the aerial parts of two new undescribed species of Phelabium, P. stellatum I. Telford & J.J. Bruhl ined. and P. sylvaticum I. Telford & J.J. Bruhl ined., has been analyzed by gas chromatography and gas chromatography coupled to mass spectrometry. Both species were found to have a similar chemical composition. The essential oil of P. stellatum was characterized by high amounts of elemol (24.6-30.8%), β-phellandrene (5.2-10.8%), β-eudesmol (6.1-10.0%), hedycaryol (4.5-9.8%), and δ-3-carene (4.4-13.7%). The main compounds of the samples of P. sylvaticum were identified as myrcene (10.6-23.0%), elemol (11.3-14.6%), β-phellandrene (0.5-14.8%), δ-3-carene (8.0-11.5%), β-eudesmol (6.7-9.1%), hedycaryol (7.4-9.7%) and α-pinene (7.1-8.9%). This is the first report of the volatile components of these two new species.
30
Strzyga-Łach, Paulina, Alicja Chrzanowska, Katarzyna Podsadni e Anna Bielenica. "Investigation of the Mechanisms of Cytotoxic Activity of 1,3-Disubstituted Thiourea Derivatives". Pharmaceuticals 14, n. 11 (28 ottobre 2021): 1097. http://dx.doi.org/10.3390/ph14111097.
Abstract (sommario):
Substituted thiourea derivatives possess confirmed cytotoxic activity towards cancer but also normal cells. To develop new selective antitumor agents, a series of 3-(trifluoromethyl)phenylthiourea analogs were synthesized, and their cytotoxicity was evaluated in vitro against the cell line panel. Compounds 1–5, 8, and 9 were highly cytotoxic against human colon (SW480, SW620) and prostate (PC3) cancer cells, and leukemia K-562 cell lines (IC50 ≤ 10 µM), with favorable selectivity over normal HaCaT cells. The derivatives exerted better growth inhibitory profiles towards selected tumor cells than the reference cisplatin. Compounds incorporating 3,4-dichloro- (2) and 4-CF3-phenyl (8) substituents displayed the highest activity (IC50 from 1.5 to 8.9 µM). The mechanisms of cytotoxic action of the most effective thioureas 1–3, 8, and 9 were studied, including the trypan blue exclusion test of cell viability, interleukin-6, and apoptosis assessments. Compounds reduced all cancerous cell numbers (especially SW480 and SW620) by 20–93%. Derivatives 2 and 8 diminished the viability of SW620 cells by 45–58%. Thioureas 1, 2, and 8 exerted strong pro-apoptotic activity. Compound 2 induced late apoptosis in both colon cancer cell lines (95–99%) and in K-562 cells (73%). All derivatives acted as inhibitors of IL-6 levels in both SW480 and SW620 cells, decreasing its secretion by 23–63%.
31
Larina, Vera N., Kirill V. Glibko e Diana A. Kasaeva. "Cardiovascular multimorbidity and temporary disability among health professionals of the multidisciplinary city hospital". CardioSomatics 10, n. 4 (15 dicembre 2019): 44–50. http://dx.doi.org/10.26442/22217185.2019.4.190573.
Abstract (sommario):
Relevance. The article highlights the topical issues of cardiovascular mulimorbidity (CVM) and temporary disability (TD) among medical workers of a large multi-profile city clinical hospital. Aim. To assess the incidence of chronic noncommunicable diseases, CVM and TD in medical workers of the city clinical hospital. Materials and methods. 527 physicians (207 men and 320 women) aged 25 to 79 (42±9.8) years and 857 nurses (32 men and 825 women) aged 19 to 79 (41±9) years were included in a retrospective, open-label study. The medical documentations analysis was performed. Results. Hypercholesterolemia was diagnosed in 38%, overweight - in 26%, obesity - in 4.8%, smoking - in 27,2%, hypertension - in 9.1%, coronary artery disease - in 3%, diabetes mellitus - in 3.2%, CVM - in 2.3% of health care workers. Over the 3-year period, 42.3% of cases of TD were recorded. TD was associated with the female sex (OR 2.4, 95% CI 1.7-3.4; p
32
Sharfman, Zachary T., Nathan Safran, Eyal Amar, Kunal Varshneya, Marc R. Safran e Ehud Rath. "Age-Adjusted Normative Values for Hip Patient-Reported Outcome Measures". American Journal of Sports Medicine 50, n. 1 (22 novembre 2021): 79–84. http://dx.doi.org/10.1177/03635465211056666.
Abstract (sommario):
Background: Patient-reported outcome measures (PROMs) are essential clinical instruments used for assessing patient function, assisting in clinical decision making, and quantifying outcomes of surgical and nonsurgical management. However, PROMs are often designed using patients with preexisting pathology and typically assume that a patient without the pathology would have a perfect or near perfect score. This may result in unrealistic expectations or falsely underestimate how well a patient is doing after treatment. The influence of age on PROMs about the hip of healthy individuals has not been studied. Hypothesis: We hypothesize that in asymptomatic individuals hip-specific PROM scores will decrease in an age-dependent manor. Study Design: Cross-sectional study; Level of evidence, 3. Methods: In this multicenter survey study, volunteers who denied preexisting hip pathology and previous hip surgery completed 3 PROMs online or as traditional paper questionnaires. The International Hip Outcome Tool (iHOT), the modified Harris Hip Score (mHHS), and the Hip Outcome Score–Activities of Daily Living (HOS-ADL) and HOS—Sport were completed. Analysis of variance with a Tukey post hoc test was used to analyze differences in PROMs among subgroups. An independent-samples Student t test and a χ2 test were used to analyze differences in continuous and categorical data, respectively. Results: In total 496, 571, 534, and 532 responses were collected for the iHOT, mHHS, HOS-ADL, and HOS–Sport, respectively. Respondents’ PROMs were scored and arranged into 3 groups by age: <40 years, 40 to 60 years, and >60 years. The iHOT, mHHS, HOS-ADL, and HOS–Sport of these asymptomatic respondents all decreased in an age-dependent manner: iHOT (<40, 94.1; 40-60, 92.4; >60, 87.0), mHHS (<40, 94.8; 40-60, 91.3; >60, 89.1), HOS-ADL (<40, 98.4; 40-60, 95.0; >60, 90.9), and HOS–Sport (<40, 95.7; 40-60, 82.9; >60, 72.9) (analysis of variance between-group differences, P < .05). Conclusion: This study demonstrated that the iHOT, mHHS, and HOS-ADL and HOS–Sport scores in asymptomatic people decrease in an age-dependent manner. It is important to compare a patient’s outcome scores with the age-normalized scores to establish an accurate reference frame with which to interpret outcomes.
33
Hillen, Wolfgang. "Architecture of Eukaryotic Genes. Herausgegeben von G. Kahl. VCH Verlagsgesellschaft, Weinheim/VCH Publishers, New York 1988. XIV, 518 S., geb. DM 195.00. – ISBN 3-527-26835-9/0-89573-809-0". Angewandte Chemie 100, n. 12 (dicembre 1988): 1806. http://dx.doi.org/10.1002/ange.19881001236.
34
Chen, Shu, Wenhui Mao, Lei Guo, Jiahui Zhang e Shenglan Tang. "Combating hepatitis B and C by 2030: achievements, gaps, and options for actions in China". BMJ Global Health 5, n. 6 (giugno 2020): e002306. http://dx.doi.org/10.1136/bmjgh-2020-002306.
Abstract (sommario):
China has the highest number of hepatitis B and C cases globally. Despite remarkable achievements, China faces daunting challenges in achieving international targets for hepatitis elimination. As part of a large-scale project assessing China’s progress in achieving health-related Sustainable Development Goals using quantitative, qualitative data and mathematical modelling, this paper summarises the achievements, gaps and challenges, and proposes options for actions for hepatitis B and C control. China has made substantial progress in controlling chronic viral hepatitis. The four most successful strategies have been: (1) hepatitis B virus childhood immunisation; (2) prevention of mother-to-child transmission; (3) full coverage of nucleic acid amplification testing in blood stations and (4) effective financing strategies to support treatment. However, the total number of deaths due to hepatitis B and C is estimated to increase from 434 724 in 2017 to 527 829 in 2030 if there is no implementation of tailored interventions. Many health system barriers, including a fragmented governance system, insufficient funding, inadequate service coverage, unstandardised treatment and flawed information systems, have compromised the effective control of hepatitis B and C in China. We suggest five strategic priority actions to help eliminate hepatitis B and C in China: (1) restructure the viral hepatitis control governance system; (2) optimise health resource allocation and improve funding efficiency; (3) improve access to and the quality of the health benefits package, especially for high-risk groups; (4) strengthen information systems to obtain high-quality hepatitis epidemiological data; (5) increase investment in viral hepatitis research and development.
35
Harris, D., B. Huang e B. Oback. "89 INHIBITION OF MAPKK AND GSK3 SIGNALLING PROMOTES DEVELOPMENT AND EPIBLAST-SPECIFIC EXPRESSION OF PLURIPOTENCY MARKERS IN BOVINE BLASTOCYSTS". Reproduction, Fertility and Development 25, n. 1 (2013): 192. http://dx.doi.org/10.1071/rdv25n1ab89.
Abstract (sommario):
During blastocyst development, the inner cell mass segregates into the epiblast and the hypoblast. These 2 tissues form morphologically and molecularly distinct cell populations that subsequently develop into the embryo proper and some extraembryonic components, respectively. In mouse, isolated epiblast cells can be directly converted into pluripotent embryonic stem cells, capable of differentiating into all cell types of an adult animal. Epiblast pluripotency is promoted by pharmacological inhibition of mitogen-activated protein kinase kinase (Mapkk). This shields epiblast cells from secreted fibroblast growth factor (Fgf), which would otherwise instruct them to exit pluripotency and differentiate into extraembryonic lineages. Indirect stimulation of the Wnt pathway by inhibiting glycogen synthase kinase 3 (GSK3) further antagonises inductive Fgf/Mapkk signalling. Thus the double inhibition (2i) of Mapkk and Gsk3 effectively promotes pluripotency (Q. L. Ying et al. 2008 Nature 453, 519–523; J. Nichols et al. 2009 Development 136, 3215–3222). We investigated the effect of 2i culture on bovine blastocysts. The IVF embryos were cultured in the presence of dimethyl sulfoxide or inhibitors of MAPKK (0.4 µM PD0325901) and GSK3 (3 µM CHIR99021) from the zygote (Day 1) stage onward. Compared to vehicle controls, 2i increased the abundance of cumulus cells in bovine IVF cultures, compromising blastocyst formation in cumulus-intact (248/823 = 30% v. 211/824 = 26%, respectively, n = 10; P < 0.05) but not cumulus-free cultures (546/1653 = 33% v. 572/1674 = 34%, respectively, n = 15; P = 0.51). In all subsequent experiments, we therefore cultured cumulus-free zygotes in 2i v. dimethyl sulfoxide until the blastocyst stage. This treatment increased the proportion of hatching (19/433 = 4% v. 7/416 = 2%, respectively, n = 10; P < 0.05) at the expense of early blastocysts (70/433 = 16% v. 93/416 = 22%, respectively, n = 11; P < 0.05). Differential staining of expanded IETS grade 1 and 2 blastocysts showed that 2i culture increased putative inner cell mass, trophectoderm, and total cell nuclei numbers by about 30% compared with controls (57 v. 43, 89 v. 69, and 146 v. 112, respectively; P < 0.01). Accelerated development and increased cell numbers were accompanied by gene expression changes in grade 1 and 2 blastocysts. Under 2i conditions, mRNA abundance of putative epiblast markers NANOG and SOX2 was >3-fold increased (P < 0.0001 and P < 0.01, respectively), and the putative hypoblast marker GATA4 was 2-fold reduced (P < 0.05). Other lineage-related markers (POU5F1, KLF4, DPPA3, and CDX2) showed no significant changes. Using microsurgical blastocyst dissection, we found that the increase in NANOG and SOX2 levels was specific to the inner cell mass-containing portion (7-fold for NANOG and 3-fold for SOX2; P < 0.00005 and P < 0.05, respectively) and not due to ectopic expression in the trophoblast-containing part, which showed similarly low expression levels for both genes. In summary, 2i treatment primed bovine blastocysts for pluripotency in the epiblast. Supported by MSI C10X1002.
36
Erofeev, Vladimir I., Sofiya N. Dzhalilova, Mikhail V. Erofeev, Vasilii S. Ripenko e Vladimir P. Reschetilowski. "Conversion of the Propane–Butane Fraction into Arenes on MFI Zeolites Modified by Zinc Oxide and Activated by Low-Temperature Plasma". Molecules 25, n. 11 (11 giugno 2020): 2704. http://dx.doi.org/10.3390/molecules25112704.
Abstract (sommario):
The effect of modification of MFI zeolite 1–5 wt.% ZnO activated by plasma on acid and catalytic properties in the conversion of the propane–butane fraction into arenes was investigated. The high-silica zeolites with silicate module 45 were synthesized from alkaline alumina–silica gels in the presence of an ‘X-oil’ organic structure-forming additive. The modification of the zeolite with zinc was carried out by impregnating the zeolite granules in the H-form with an aqueous solution of Zn(NO3)2. The obtained zeolites were characterized by X-ray phase analysis and IR spectroscopy. It is shown that the synthesized zeolites belong to the high-silica MFI zeolites. The study of microporous zeolite-containing catalysts during the conversion of C3-C4 alkanes to aromatic hydrocarbons made it possible to establish that the highest yield of aromatic hydrocarbons is observed on zeolite catalysts modified with 1 and 3% ZnO and amount to 63.7 and 64.4% at 600 °C, respectively, which is 7.7–8.4% more than on the original zeolite. The preliminary activation of microporous zeolites modified with 1–5% ZnO and plasma leads to an increase in the yield of aromatic hydrocarbons from the propane–butane fraction; the maximum yield of arenes is observed in zeolite catalysts modified with 1 and 3% ZnO and activated by plasma, amounting to 64.9 and 65.5% at 600 °C, respectively, which is 8.9–9.5% more than on the initial zeolite. The activity of the zeolite catalysts modified by ZnO and activated by plasma show good agreement with their acid properties. Activation of the zeolites modified by 1 and 3% ZnO and plasma leads to an increase in the concentration of the weak acid sites of the catalyst to 707 and 764 mmol/g in comparison with plasma-inactivated 1 and 3% ZnO/ZKE-XM catalysts at 626 and 572 mmol/g, respectively.
37
Minckwitz, G. Von, S. Kümmel, P. Vogel, C. Hanusch, H. Eidtmann, J. Hilfrich, B. Gerber, J. Huober, S. D. Costa e S. Loibl. "Inflammatory and locally advanced breast cancer respond similar to operable breast cancer to neoadjuvant chemotherapy: Results from 278 patients with cT4a-d tumors of the GeparTRIO trial". Journal of Clinical Oncology 25, n. 18_suppl (20 giugno 2007): 542. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.542.
Abstract (sommario):
542 Background: Neoadjuvant chemotherapy is the treatment of choice in patients with T4a-c and inflammatory (T4d) breast cancer. However, data on large-scale, multicentre, prospective trials are missing. In the GeparTRIO study (SABCS 2006, abstr. 42) 278 of 2,090 patients with cT4a-c or T4d tumors were included as a separate stratum for inoperable disease for a prospectively planned analysis. Methods: Patients were treated with 2 cycles TAC (docetaxel 75 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2, q d 21). If tumor reduction was >50%, patients were randomized to receive 4 or 6 additional TAC cycles. If tumor reduction was less, patients were randomized to 4 additional TAC cycles or to 4 NX cycles (vinorelbine 25 mg/m2 day 1 + 8, capecitabine 2,000 mg/m2 day 1 14, q21). Efficacy endpoints were pCR-rate (no invasive and no non-invasive residuals in breast and lymph nodes) (primary), clinical response before surgery and breast conserving therapy (BCT) rate (secondary). Results: 95 (4.6%) T4d, 183 (8.9%) cT4a-c, and 1,767 (86.4%) T1–3 tumors were registered in GeparTRIO within 36 months. Patients with inoperable/operable tumors had a median age of 53.9/49.0 years, median cT size: 7.0/4.0cm, cN+: 75.6/52.0%, ductal: 76.3/78.4%, lobular: 14.0/13.5%, multiple lesions: 28.5/19.5%, grade 3: 34.8/39.9%, hormone receptor (HR) neg: 24.7/36.6%, HER-2 pos: 41.0/35.5%. Response rates for T4d, T4a-c, T1–3 were 8.4, 10.9, 17.5% (pCR, p=0.007), 36.7, 59.4, 72.6% (palpation after 2 cycles TAC, p<0.0001), 64.2, 62.3, 77.8% (palpation before surgery, p<0.0001), 52.6, 51.9, 67.4% (ultrasound before surgery, p<0.0001). BCT was performed in 12.6, 31.7, 69.5% (p<0.0001). Response after two cycles, negative HR content, young age, high grade, ductal type, but not tumor stage or size, were independent predictors for pCR in the total population. Conclusions: Inflammatory and cT4a-c breast carcinomas, compared to cT1–3 tumors, show less favorable tumor characteristics but a comparable pattern of response to TAC/NX. These patients do not need separate neoadjuvant trials. [Table: see text]
38
Butler, Andrew J., Justiss Kallos, Stephen N. Housley, Michelle C. LaPlaca, Stephen F. Traynelis e Steven L. Wolf. "Randomized, Placebo-Controlled, Double-Blind Pilot Study of D-Cycloserine in Chronic Stroke". Rehabilitation Research and Practice 2015 (2015): 1–14. http://dx.doi.org/10.1155/2015/534239.
Abstract (sommario):
Stroke is a leading cause of death and disability in the USA. Up to 60% of patients do not fully recover despite intensive physical therapy treatment. N-Methyl-D-aspartate receptors (NMDA-R) have been shown to play a role in synaptic plasticity when activated. D-Cycloserine promotes NMDA receptor function by binding to receptors with unoccupied glycine sites. These receptors are involved in learning and memory. We hypothesized that D-cycloserine, when combined with robotic-assisted physiotherapy (RAP), would result in greater gains compared with placebo + RAP in stroke survivors. Participants (n=14) were randomized to D-cycloserine plus RAP or placebo plus RAP. Functional, cognitive, and quality-of-life measures were used to assess recovery. There was significant improvement in grip strength of the affected hand within both groups from baseline to 3 weeks (95% confidence interval for mean change, 3.95 ± 2.96 to 4.90 ± 3.56 N for D-cycloserine and 5.72 ± 3.98 to 8.44 ± 4.90 N for control). SIS mood domain showed improvement for both groups (95% confidence interval for mean change, 72.6 ± 16.3 to 82.9 ± 10.9 for D-cycloserine and 82.9 ± 13.5 to 90.3 ± 9.9 for control). This preliminary study does not provide evidence that D-cycloserine can provide greater gains in learning compared with placebo for stroke survivors.
39
Volles, David F., James M. McKenney, W. Greg Miller, David Ruffen e Dongbo Zhang. "Analytic and Clinical Performance of Two Compact Cholesterol‐Testing Devices". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 18, n. 1 (2 gennaio 1998): 184–92. http://dx.doi.org/10.1002/j.1875-9114.1998.tb03837.x.
Abstract (sommario):
Several relatively inexpensive compact analyzers for measuring cholesterol are available for use outside of the clinical laboratory. We evaluated the analytic and clinical performance of total cholesterol assayed with the AccuMeter (ChemTrak) and the LDX (Cholestech). Accuracy of both devices was evaluated by collecting capillary and venous whole blood from 100 subjects and assaying for total cholesterol. Results were compared with the Centers for Disease Control standardized reference laboratory method. Mean percent bias, mean absolute percent bias, and percentage of subjects with total error above ± 8.9% were calculated and results were compared with recommendations from National Cholesterol Education Program (NCEP) for total cholesterol measurements. Precision was evaluated by assay of three pooled serum samples with both devices in duplicate in two runs/day for 20 days. The CV for each serum pool for each device was calculated and compared with NCEP recommendations for precision for total cholesterol measurements. Results with the two devices were compared. The total cholesterol mean percent bias for capillary samples was 2.1% for the LDX and −1.0% for the AccuMeter (p<0.01), and for venous samples 1.6 and −2.0%, respectively (p<0.001). The mean absolute percent bias for capillary samples was 5.4 and 5.2%, respectively (p=0.29), and for venous samples was 5.0 and 5.7% (p=0.79). Each device had an excessive number (12–22%) of individual results that exceeded NCEP recommended total error for a single cholesterol measurement (± 8.9%). In the precision analysis the average CV from all three serum pools was 4.0% and 5.3% for the LDX and AccuMeter, respectively (p<0.05). Thus both devices failed to meet the NCEP recommendation for precision of 3% CV. They both provided total cholesterol results that correctly classified individual patients into appropriate risk groups 95% of the time or better if values within ± 8.9% of NCEP cut points for risk classification were ignored. Both devices met the NCEP ± 3% requirement for total cholesterol mean percent bias but did not meet the ± 3% requirement for CV as a measure of precision. Because of the variability in results, both devices had excessive numbers of individual subjects with total cholesterol results greater than the recommended total error limit of ± 8.9% difference from the standardized method. Despite variability in some individual results, the rate of clinical misclassifications for coronary heart disease risk was relatively low for both devices if results near the NCEP cut points were repeated.
40
KRISTENSEN, G. B., I. VERGOTE, G. STUART, J. M. DEL CAMPO, J. KÆRN, M. BAEKELANDT, A. B. LOPEZ et al. "First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival". International Journal of Gynecologic Cancer 15, Suppl 3 (novembre 2005): 221. http://dx.doi.org/10.1136/ijgc-00009577-200511001-00005.
Abstract (sommario):
Adding anthracyclin to conventional platinum-based chemotherapy of ovarian cancer has been found to improve survival. The aim of this study was to evaluate the effect on survival on adding epirubicin to the standard treatment with carboplatin and paclitaxel. Between March 1999 and August 2001, 887 patients with epithelial ovarian, tubal, or peritoneal cancer FIGO stage IIB–IV were enrolled. They were randomized to receive six to nine cycles of paclitaxel (175 mg/m2, 3 h iv) followed by carboplatin (AUC 5, Calvert formula) with or without epirubicin (75 mg/m2iv prior to paclitaxel) on a 3-weekly schedule. The primary end point was progression-free survival, and 542 progression events were required to detect a hazard ratio of 0.786 or less. Patient characteristics were similar across the treatment arms. Residual disease less than 1 cm at surgery with no measurable disease before chemotherapy was reported in 328 patients (37%), with 159 in the TEC arm and 169 in the TC arm. A total of 63 patients had to be withdrawn from the study: 20 due to ineligibility, 32 due to hypersensitivity reaction to paclitaxel during the first or second course, and 11 due to withdrawal of informed consent, leaving 824 patients for the survival analysis. The median follow-up is 30 months for patients still alive. Progressive disease has been reported for 573 patients, and 326 have died. In the total group of patients, the median time to progression was 17.2 months in the TEC arm and 16.3 in the TC arm (P= 0.99). In the group with residual tumor of 1 cm or less, the median time to progression was 24.7 months in the TEC arm and 24.4 months in the TC arm (P= 0.94). In patients with more than 1 cm of residual tumor, the median time to progression in the TEC arm was 14.6 months and 13.8 months in the TC arm (P= 0.75). The median overall survival has not yet been reached. The addition of epirubicin to the standard carboplatin and paclitaxel treatment did not improve progression-free survival. The evaluation of effect on long-term survival awaits further follow-up.
41
Kano, Yutaka, Danielle J. Padilla, Brad J. Behnke, K. Sue Hageman, Timothy I. Musch e David C. Poole. "Effects of eccentric exercise on microcirculation and microvascular oxygen pressures in rat spinotrapezius muscle". Journal of Applied Physiology 99, n. 4 (ottobre 2005): 1516–22. http://dx.doi.org/10.1152/japplphysiol.00069.2005.
Abstract (sommario):
A single bout of eccentric exercise results in muscle damage, but it is not known whether this is correlated with microcirculatory dysfunction. We tested the following hypotheses in the spinotrapezius muscle of rats either 1 (DH-1; n = 6) or 3 (DH-3; n = 6) days after a downhill run to exhaustion (90–120 min; −14° grade): 1) in resting muscle, capillary hemodynamics would be impaired, and 2) at the onset of subsequent acute concentric contractions, the decrease of microvascular O2 pressure (P mvo2), which reflects the dynamic balance between O2 delivery and O2 utilization, would be accelerated compared with control (Con, n = 6) rats. In contrast to Con muscles, intravital microscopy observations revealed the presence of sarcomere disruptions in DH-1 and DH-3 and increased capillary diameter in DH-3 (Con: 5.2 ± 0.1; DH-1: 5.1 ± 0.1; DH-3: 5.6 ± 0.1 μm; both P < 0.05 vs. DH-3). At rest, there was a significant reduction in the percentage of capillaries that sustained continuous red blood cell (RBC) flux in both DH running groups (Con: 90.0 ± 2.1; DH-1: 66.4 ± 5.2; DH-3: 72.9 ± 4.1%, both P < 0.05 vs. Con). Capillary tube hematocrit was elevated in DH-1 but reduced in DH-3 (Con: 22 ± 2; DH-1: 28 ± 1; DH-3: 16 ± 1%; all P < 0.05). Although capillary RBC flux did not differ between groups ( P > 0.05), RBC velocity was lower in DH-1 compared with Con (Con: 324 ± 43; DH-1: 212 ± 30; DH-3: 266 ± 45 μm/s; P < 0.05 DH-1 vs. Con). Baseline P mvO2 before contractions was not different between groups ( P > 0.05), but the time constant of the exponential fall to contracting P mvO2 values was accelerated in the DH running groups (Con: 14.7 ± 1.4; DH-1: 8.9 ± 1.4; DH-3: 8.7 ± 1.4 s, both P < 0.05 vs. Con). These findings are consistent with the presence of substantial microvascular dysfunction after downhill eccentric running, which slows the exercise hyperemic response at the onset of contractions and reduces the P mvO2 available to drive blood-muscle O2 delivery.
42
Seo, Jae Hyeon, Ho Seong Lee, Young Rak Choi, Seung Hwan Park, Jae Hyung Lee e Hannah Chun. "Outcomes of Simultaneous Bilateral vs Unilateral Distal Chevron Metatarsal Osteotomy in Hallux Valgus Patients Aged ≥60 Years". Foot & Ankle International 42, n. 7 (29 marzo 2021): 919–28. http://dx.doi.org/10.1177/1071100721996707.
Abstract (sommario):
Background: The purpose of this study was to compare radiographic outcomes of simultaneous bilateral and unilateral distal chevron metatarsal osteotomy (DCMO) in hallux valgus patients aged ≥60 years. Methods: This retrospective study analyzed consecutive outcomes of simultaneous bilateral DCMO and unilateral DCMO performed between June 2010 and August 2018 in 90 feet of 60 patients. Thirty patients underwent simultaneous bilateral DCMO, and 30 underwent unilateral DCMO. Comparative analysis of radiographic and clinical parameters between a simultaneous bilateral DCMO group (SB) and a unilateral DCMO group (U) was performed. Results: Mean age at surgery (65.7±4.8 vs 65.2±5.2 years), mean length of follow-up period (20.0 vs 18.6 months), and preoperative radiographic parameters were similar between the 2 groups (SB vs U). Mean hallux valgus angle (HVA) improved from 34.2 to 5.4 degrees (correction angle SB 28.8 vs U 28.8 degrees). Mean first-to-second intermetatarsal angle improved from 15.8 to 6.8 degrees (correction angle SB 8.9 vs U 8.9 degrees). Hallux varus deformity was observed in 4 feet (SB 3 vs U 1), and mechanical instability with callus formation in 1 foot in the unilateral group. Conclusion: DCMOs in patients aged ≥60 years were radiographically effective and safe, even performed in one stage bilaterally. Radiographic parameters were similar in patients who underwent simultaneous bilateral and unilateral DCMO. Level of Evidence: Level III, retrospective cohort study.
43
Garbuz, V. V., V. A. Petrova, T. A. Silinskaya, T. F. Lobunets, O. I. Bykov, V. B. Muratov, T. M. Terentyeva et al. "Specific surface area, crystallite size and thermokinetic of oxide formation γ → α-Al2O3 nano powders at 570 – 1470 K". Surface 12(27) (30 dicembre 2020): 146–52. http://dx.doi.org/10.15407/surface.2020.12.146.
Abstract (sommario):
Powders where the γ≈α-Al2O3-nano phases are the priority precursors for catalysts for heterogeneous catalysis with the maximum content of surface 5-coordinated Al centers for Pt attachment. Hydrogenated nano powders (~8 nm) of γ-, γ '-, θ-, κ-Al2O3 soluble in hydrochloric acid were obtained from the processing of aluminum boride powders with an icosahedral structure. Samples, which underwent a step-by-step and single heating of 50-100K heat treatment for 2 hours at temperatures of 570-1470K, were received in quantity of 34. The specific surface area of SВET, m2g-1 was measured by the thermal nitrogen desorption express method of gas chromatography through the GC-1 device. X-ray (phase and coherent), fluorescence and phase chemical-analytical evaluation of the samples were performed. The thermokinetic characteristics of the processes are calculated using the exponential Arrhenius law. Dimensional characteristics of crystallites (10.4-48 nm); specific surface area of powders (213-8.6 m2g-1, SВET); thermokinetic parameters of α-Al2O3 crystallite growth process (V α-Al2O3 - 1.44 10-3 - 6.67 10-3 nm s-1; E α-Al2O3 = 38.7±2.1kJ mol-1; A0 = 0.16±0.0 s-1 along the temperature line 1220-1470K were determined and calculated. The process of dehydration of two OH-groups occurs in the region 570-720K Ea H2O ↑ = 30.5 ± 0.5 kJ mol-1 A0 = 1.33±0.3 s-1. The last group of OH at temperatures of 820 -1070К and a rate of 2.13 10-4 - 4.93 10-4 mol s-1 Ea H2O ↑ = 13.2 ± 0.8 kJ mol-1 A0 = 16.9 ± 0.9 s-1. The activation energy of the phase transition is Ea., γ → α-Al2O3 = 23.9 ± 1.0 kJ mol-1 A0 = 2.01 ± 0.72 s-1 (770-970K) and Ea., γ → α-Al2O3 = 83.5 ± 0.8 kJ mol-1 A0 =(2,05±0,95) 103 s-1 (1070-1170K). It agrees well with the known heat of conversion Eа, γ→α-Al2O3 = 85 kJ mol-1. The TK of γ≈α-Al2O3-nano phases is at 1170K.
44
Forsblad-D’elia, H., A. Wiginder, C. Sahlin-Ingridsson, M. Geijer, K. Franklin e A. Blomberg. "POS0957 THE PREVALENCE AND FACTORS RELATED TO SLEEP APNOEA IN ANKYLOSING SPONDYLITIS". Annals of the Rheumatic Diseases 80, Suppl 1 (19 maggio 2021): 743.1–743. http://dx.doi.org/10.1136/annrheumdis-2021-eular.823.
Abstract (sommario):
Background:An increased prevalence of obstructive sleep apnoea (OSA) has been suggested in ankylosing spondylitis (AS), but few controlled studies have been performed.Objectives:We thus aimed to study the prevalence of OSA in patients with AS compared to controls and to study if disease-related and non-disease-related factors were determinants of OSA in AS patients.Methods:One hundred and fifty-five patients with AS were included in the Backbone study that investigates severity and comorbidities in AS. Controls were recruited from the Swedish CardioPulmonary bioImage Study (SCAPIS). Participants were asked to be examined with a home sleep-monitoring device during one night’s sleep to evaluate the presence of OSA. For each AS patient, 45-70 years, four controls were matched for sex, age, weight and height. OSA was defined as an apnoea-hypopnea-index ≥5 events/hour.Results:In total, 63/155(40.6%) patients with AS were examined with a home sleep-monitoring device out of which 46 patients were 45-70 years and therefore matched (mean age 57.2±7.5years, 30(65.2%) men) with 179 controls (mean age 57.2±4.5years, 123(68.7%) men). Twenty-two out of 46(47.8%) patients with AS vs. 91/179(50.8%) controls had OSA, p=0.72. No differences measurements evaluating OSA were noted in AS vs. controls. In logistic regression analysis, based on all 63 examined AS-patients, several AS-related variables were associated with OSA but after adjusting for age and sex, only higher age and BMI, remained to be significant determinants of OSA, Table 1.Table 1.Univariable and age- and sex-adjusted logistic regression analyses with obstructive sleep apnoea as dependent variable in 63 patients with ankylosing spondylitis.VariablesUnivariable logistic regression analyses, Odds Ratio (95%CI)PAge- and sex-adjusted logistic regression analyses,Odds Ratio (95%CI)PSex, male1.9(0.6-5.5)0.251.5(0.4-4.8)0.53Age1.1(1.0-1.2)0.0021.1(1.0-1.2)0.002BMI1.4(1.1-1.7)0.0011.6(1.2- 2.2)0.001Duration of symptoms1.1(1.0-1.1)0.0281.0(0.9-1.1)0.79BASMI1.9(1.3-2.9)0.0021.5(0.9 -2.5)0.87BASFI1.4(1.0-2.0)0.0381.3(0.9-2.0)0.88≥1 Syndesmophyte3.9(1.3-12.2)0.0173.0(0.8-11.3)0.10mSASSS1.0(1.0-1.1)0.0471.0(0.98-1.05)0.25Metabolic syndrome4.3(1.5-12.9)0.0081.4(0.3-6.6)0.69Epworth Sleep Scale1.2(1.0-1-3)0.0231.2(1.0-1.4)0.29Conclusion:In this case-control study, patients with AS did not have a higher prevalence of OSA compared to controls. AS patients with OSA had higher BMI and were older compared to patients without OSA.Disclosure of Interests:None declared.
45
Mangukia, Chirantan, Mehul Kachhadia e Manish Meswani. "Fast-track off-pump coronary artery bypass: single-center experience". Asian Cardiovascular and Thoracic Annals 27, n. 4 (24 febbraio 2019): 256–64. http://dx.doi.org/10.1177/0218492319833266.
Abstract (sommario):
Aim The primary goal of the study was to perform retrospective analysis of fast-track coronary artery bypass grafting at our institute to identify risk factors for prolonged hospital stay. A secondary goal was to identify and compare survival statistics with those published in literature. Method We performed a retrospective analysis of patients enrolled in our fast-track coronary artery bypass protocol. There were 709 patients with a mean age of 58.85 ± 8.9 years; 572 were men. The mean EuroSCORE II was 2.02% ± 2.64%. Of these 709 patients, 538 (76%) met the requirements for discharge within 100 hours. Results Prolonged ventilation or reintubation, major pulmonary complications, gastrointestinal and neurological complications were the strongest predictors of fast-track failure. Persistent atrial fibrillation, postoperative transient renal impairment, requirement for noninvasive ventilation > 3 times, sternal wound infection, insulin-dependent diabetes mellitus, preoperative intraaortic balloon pump for chest pain or ST changes, preoperative severe left ventricular dysfunction, preoperative severe renal impairment, and peripheral arterial disease were also found to be significant risk factors for fast-track failure. Cumulative survival at 66 months of follow-up was 90.2% ± 0.02%. Conclusion The risk factors listed above were associated with fast-track failure. Smoking cessation helps to nullify the factor of chronic obstructive pulmonary disease. Intraoperative elective insertion of a balloon pump does not affect the fast-track protocol. Survival was comparable to that described in the literature.
46
John, Thomas, Sean Tighe, Hosam Sheha, Pedram Hamrah, Zeina M. Salem, Anny M. S. Cheng, Ming X. Wang e Nathan D. Rock. "Corneal Nerve Regeneration after Self-Retained Cryopreserved Amniotic Membrane in Dry Eye Disease". Journal of Ophthalmology 2017 (2017): 1–10. http://dx.doi.org/10.1155/2017/6404918.
Abstract (sommario):
Purpose. To evaluate the efficacy of self-retained cryopreserved amniotic membrane (CAM) in promoting corneal nerve regeneration and improving corneal sensitivity in dry eye disease (DED).Methods. In this prospective randomized clinical trial, subjects with DED were randomized to receive CAM (study group) or conventional maximum treatment (control). Changes in signs and symptoms, corneal sensitivity, topography, and in vivo confocal microscopy (IVCM) were evaluated at baseline, 1 month, and 3 months.Results. Twenty subjects (age 66.9 ± 8.9) were enrolled and 17 completed all follow-up visits. Signs and symptoms were significantly improved in the study group yet remained constant in the control. IVCM showed a significant increase in corneal nerve density in the study group (12,241 ± 5083 μm/mm2at baseline, 16,364 ± 3734 μm/mm2at 1 month, and 18,827 ± 5453 μm/mm2at 3 months,p=0.015) but was unchanged in the control. This improvement was accompanied with a significant increase in corneal sensitivity (3.25 ± 0.6 cm at baseline, 5.2 ± 0.5 cm at 1 month, and 5.6 ± 0.4 cm at 3 months,p<0.001) and corneal topography only in the study group.Conclusions. Self-retained CAM is a promising therapy for corneal nerve regeneration and accelerated recovery of the ocular surface health in patients with DED. The study is registered at clinicaltrials.gov with trial identifier:NCT02764814.
47
Swor, Kathy, Prabodh Satyal, Sunita Timsina e William N. Setzer. "Chemical Composition and Terpenoid Enantiomeric Distribution of the Essential oil of Artemisia tridentata Subsp. tridentata From Southwestern Idaho". Natural Product Communications 17, n. 7 (luglio 2022): 1934578X2211174. http://dx.doi.org/10.1177/1934578x221117417.
Abstract (sommario):
Big sagebrush ( Artemisia tridentata) is a common shrub growing in the cold intermountain regions of western North America. The plant is an important food source for herbivores and was used in Native American traditional medicine. In this work, the essential oils were obtained from 3 individuals of A tridentata subsp. tridentata growing in southwestern Idaho. The essential oils were analyzed by gas chromatographic methods including chiral gas chromatography. The major components in the essential oils were yomogi alcohol (5.8%-30.8%), santolina epoxide (1.7%-10.5%), camphor (5.2%-20.1%), and ( Z)-tagetone (0.9%-8.9%). ( + )-α-Pinene, ( + )-β-pinene, ( + )-verbenone, ( − )-( E)-β-caryophyllene, and ( − )-δ-cadinene were the only enantiomers observed for these compounds. Camphene and camphor, on the other hand, showed wide variability in enantiomeric distribution. The enantiomeric distributions in A tridentata subsp. tridentata differ widely compared to other Artemisia species. There are large variations in the chemical compositions in A tridentata, both between subspecies and within subspecies.
48
Piya, Sujan, Seemana Bhattacharya, Hong Mu, Philip L. Lorenzi, Teresa McQueen, Eric Richard Davis, Vivian Ruvolo et al. "BRD4 Proteolysis Targeting Chimera (PROTAC) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects". Blood 128, n. 22 (2 dicembre 2016): 748. http://dx.doi.org/10.1182/blood.v128.22.748.748.
Abstract (sommario):
Abstract Background: Mutational or non-mutational epigenetic events that aberrantly modify the chromatin regulatory machinery to enhance oncogene expression are a hallmark of myeloid malignancies. BRD4, a member of the bromodomain and extra terminal domain (BET) family, is a transcriptional coactivator that co-occupies super enhancer complexes associated with transcription of oncogenes (MYC, SOX2, NF-kB etc.) - and apoptosis regulators (Bcl-2, Bcl-XL, etc.) and has been validated as a target in AML therapy1. ARV-825 is a hetero-bifunctional PROteolysis TArgeting Chimera (PROTAC) that recruits BRD4 to the E3 ubiquitin ligase cereblon and leads to efficient and sustained degradation of BRD4 resulting in down-regulation of MYC2. Objectives: We examined the anti-leukemic effect of ARV-825 against AML cell lines, primary AML blasts and a mouse model of disseminated leukemia. Since tumor-stroma interactions driven by oncogene activation play a major role in resistance to AML therapy, we tested whether ARV-825 could overcome stroma-mediated drug resistance. As MYC harmonizes nutrient acquisition by cancer cells through regulation of the metabolites antiporter systems (SLC7A11, SLC5A5) 3, we profiled changes in a few important amino acids and organic acids in AML cell in response to ARV-825. Results : The IC50s for all tested cell lines and primary AML cells at 72 hours were in the low nanomolar range (2-50 nM) and 10-100 times lower than JQ1, a small molecule BRD4 inhibitor. ARV-825 induces sustained BRD4 degradation accompanied by down-regulation of targets such as MYC, anti-apoptotic BCL-2 family molecules and an increase in apoptosis and DNA damage4. In an in vitro tumor-stroma co-culture model including hypoxic conditions, bone marrow derived mesenchymal stromal cells (MSCs) protected OCI-AML3 cells from cytarabine ( 55.4% apoptosis with vs. 35.0% without MSCs in normoxia and 50.6% vs. 32.8%, respectively, in hypoxia), but no such protection was observed against ARV-825 (58.7% apoptosis vs. 55.2% in normoxia and 57.4% vs. 58.3%, respectively, in hypoxia). Mass cytometry based proteomic analysis (CyTOF) (Fig. 1), immunoblotting and flow cytometry showed that among apoptotic, cell adhesion and signaling proteins, MYC, CD44 and surface CXCR4 were the most down-regulated proteins in AML cells. The functional relevance of surface CXCR4 down regulation was confirmed in migration assays against the CXCR4 ligand SDF-1. Phosphorylation of CXCR4 by PIM1 kinase is necessary for surface expression of CXCR4, ARV-825 treatment reduced PIM1 levels and phosphorylation of CXCR4 in AML cells while overexpression of PIM1 or Myc reversed the phenomena. Quantitative PCR and immunoblotting analysis confirmed the transcriptional down regulation of total CD44 and CD44 variants 8-10 (2-fold change treated vs. untreated). As a functional correlate of CD44 variants, mass spectrometry based intracellular metabolomics and flow cytometry confirmed reduction in cysteine uptake and increased reactive oxygen species (ROS) generation (Fig. 2). Additional metabolic readouts using the Sea horse system revealed inhibition of mitochondrial respiration as indicated by decreased in oxygen consumption rate and production of ATP upon treatment of ARV-825. Furthermore, array based gene expression profiling showed down-regulation of additional amino acid transporters and the Wnt/β-catenin pathway. Finally, in a mouse model of human leukemia, the leukemia burdens were significantly lower in the ARV-825 treated mice as confirmed by luciferase imaging, flow cytometry, spleen size and survived longer compared to control mice (p=0.0005) (Fig.3). Conclusion : ARV-825 has substantial, broad anti-AML activity and importantly modulates the tumor microenvironment and metabolism to overcome stroma-mediated drug resistance. Together, our data suggest that ARV-825 is an effective in targeting BET family of proteins for the treatment of AML Reference: 1. Nature 2011; 478(7370): 524-528. doi: 10.1038/nature10334 2. Chem Biol 2015; 22(6): 755-763. doi: 10.1016/j.chembiol.2015.05.009 3. Cancer Res 2015; 75(9): 1782-1788. doi: 10.1158/0008-5472.CAN-14-3745 4. 604(675): ASH 2015,San franscisco,USA. Disclosures Lorenzi: Erytech Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties: NIH-held patent related to L-asparaginase. Qian:Arvinas, LLC: Employment. Kantarjian:Bristol-Myers Squibb: Research Funding; ARIAD: Research Funding; Amgen: Research Funding; Pfizer Inc: Research Funding; Delta-Fly Pharma: Research Funding; Novartis: Research Funding.
49
Sánchez-Carrasco, Miguel, Juan C. Rodríguez-Sanjuán, Fernando Martín-Acebes, Francisco J. Llorca-Díaz, Manuel Gómez-Fleitas, Rocío Zambrano Muñoz e F. Javier Sánchez-Manuel. "Evaluation of Early Cholecystectomy versus Delayed Cholecystectomy in the Treatment of Acute Cholecystitis". HPB Surgery 2016 (10 ottobre 2016): 1–8. http://dx.doi.org/10.1155/2016/4614096.
Abstract (sommario):
Objective. To evaluate if early cholecystectomy (EC) is the most appropriate treatment for acute cholecystitis compared to delayed cholecystectomy (DC). Patients and Methods. A retrospective cohort study of 1043 patients was carried out, with a group of 531 EC cases and a group of 512 DC patients. The following parameters were recorded: (1) postoperative hospital morbidity, (2) hospital mortality, (3) days of hospital stay, (4) readmissions, (5) admission to the Intensive Care Unit (ICU), (6) type of surgery, (7) operating time, and (8) reoperations. In addition, we estimated the direct cost savings of implementing an EC program. Results. The overall morbidity of the EC group (29.9%) was significantly lower than the DC group (38.7%). EC demonstrated significantly better results than DC in days of hospital stay (8.9 versus 15.8 days), readmission percentage (6.8% versus 21.9%), and percentage of ICU admission (2.3% versus 7.8%), which can result in reducing the direct costs. The patients who benefited most from an EC were those with a Charlson index > 3. Conclusions. EC is safe in patients with acute cholecystitis and could lead to a reduction in the direct costs of treatment.
50
Firman, Nicola, Marta Wilk, Milena Marszalek, Lucy Griffiths, Gill Harper e Carol Dezateux. "Is obesity more likely among children sharing a household with an older child with obesity? Cross-sectional study of linked National Child Measurement Programme data and electronic health records". BMJ Paediatrics Open 8, n. 1 (aprile 2024): e002533. http://dx.doi.org/10.1136/bmjpo-2024-002533.
Abstract (sommario):
Background/objectivesWe identified household members from electronic health records linked to National Child Measurement Programme (NCMP) data to estimate the likelihood of obesity among children living with an older child with obesity.MethodsWe included 126 829 NCMP participants in four London boroughs and assigned households from encrypted Unique Property Reference Numbers for 115 466 (91.0%). We categorised the ethnic-adjusted body mass index of the youngest and oldest household children (underweight/healthy weight <91st, ≥91st overweight <98th, obesity ≥98th centile) and estimated adjusted ORs and 95% CIs of obesity in the youngest child by the oldest child’s weight status, adjusting for number of household children (2, 3 or ≥4), youngest child’s sex, ethnicity and school year of NCMP participation.ResultsWe identified 19 702 households shared by two or more NCMP participants (% male; median age, range (years)—youngest children: 51.2%; 5.2, 4.1–11.8; oldest children: 50.6%; 10.6, 4.1–11.8). One-third of youngest children with obesity shared a household with another child with obesity (33.2%; 95% CI: 31.2, 35.2), compared with 9.2% (8.8, 9.7) of youngest children with a healthy weight. Youngest children living with an older child considered overweight (OR: 2.33; 95% CI: 2.06, 2.64) or obese (4.59; 4.10, 5.14) were more likely to be living with obesity.ConclusionsIdentifying children sharing households by linking primary care and school records provides novel insights into the shared weight status of children sharing a household. Qualitative research is needed to understand how food practices vary by household characteristics to increase understanding of how the home environment influences childhood obesity.